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Streptococcus pneumoniae is an opportunistic human pathogen. The progression 
from asymptomatic carriage to disease (e.g. middle-ear infection, pneumonia, 
sepsis, or meningitis) depends on factors characteristic of pneumococcal 
strains as well as host defenses. The polysaccharide capsule surrounding the 
bacterium inhibits deposition of complement on the bacterial surface and 
thereby helps it to escape recognition by phagocytic cells. Differences in the 
capsule composition permit differentiation between >90 capsular types, some 
of which are frequently associated with invasive disease, others rarely. Clinical 
data suggest that protection from pneumococcal disease by conjugate vaccines 
may depend on the capsular serotype. 
The aim of this thesis was to find reasons for the serotype-related differences 
observed in disease potential and vaccine efficacy. The results suggest that 
invasive serotypes are better adapted to resist host immunity. Vaccine-induced 
antibodies in higher quantity or quality are needed for efficient protection 
against such serotypes. This study adds to our understanding of the mechanisms 
whereby pneumococcus evades complement and how vaccines made from 
pneumococcal virulence factors could prevent disease.
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ABSTRACT 
Merit Melin. Interplay of Virulence Factors in Complement Resistance of 
Streptococcus pneumoniae. National Institute for Health and Welfare (THL), 
Research 58. 167 pages. Helsinki, Finland 2011. 
ISBN 978-952-245-459-1 (printed), ISBN 978-952-245-460-7 (pdf) 
 
Streptococcus pneumoniae (pneumococcus) is a normal inhabitant of the human 
nasopharynx. Symptoms occur in only a small proportion of those who become 
carriers, but the ubiquity of the organism in the human population results in a large 
burden of disease. S. pneumoniae is the leading bacterial cause of pneumonia, 
sepsis, and meningitis worldwide, causing the death of a million children each year. 
Middle-ear infection is the most common clinical manifestation of mucosal 
pneumococcal infections. In invasive disease, S. pneumoniae gains access to the 
bloodstream and spreads to normally sterile parts of the body. The progression from 
asymptomatic colonization to disease depends on factors characteristic of specific 
pneumococcal strains as well as the status of host defenses. The polysaccharide 
capsule surrounding the bacterium is considered to be the most important factor 
affecting the virulence of pneumococci. It protects pneumococci from phagocytosis 
and also may determine its affinity to the respiratory epithelium. S. pneumoniae as a 
species comprises more than 90 different capsular serotypes, but not all of them are 
equally prevalent in human diseases. “Invasive” serotypes are rarely isolated from 
healthy carriers, but relatively often cause invasive disease. Serotypes that are 
carried asymptomatically for a long time behave like opportunistic pathogens, 
causing disease in patients who have impaired immune defenses.  
 
The complement system is a collection of blood and cell surface proteins that act as 
a major primary defense against invading microbes. Phagocytic cells with receptors 
for complement proteins can engulf and destroy pneumococcal cells opsonized with 
these proteins. S. pneumoniae has evolved a number of ways to subvert mechanisms 
of innate immunity, and this is likely to contribute to its pathogenicity. The capsular 
serotype, proteins essential for virulence, as well the genotype, may all influence the 
ability of pneumococcus to resist complement and its potential to cause disease. 
Immunization with conjugate vaccines produces opsonic antibodies, which enhance 
complement deposition and clearance of the bacteria. The pneumococcal vaccine 
included in the Finnish national immunization program in 2010 contains the most 
common serotypes causing invasive disease. Clinical data suggest that protection 
from middle-ear infection and possibly also from invasive disease depends largely 
on the capsular serotype, for reasons hitherto unknown. 
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The general aim of this thesis is to assess the relative roles of the pneumococcal 
capsule and virulence proteins in complement evasion and subsequent 
opsonophagocytic killing. The main question is whether differences between 
serotypes to resist complement explain the different abilities of serotypes to cause 
disease. The importance of particular virulence factors to the complement resistance 
of a strain may vary depending on its genotype. Prior studies have evaluated the 
effect of the capsule and virulence proteins on complement resistance of S. 
pneumoniae by comparing only a few strains. In this thesis, the role of 
pneumococcal virulence factors in the complement resistance of the bacterium was 
studied in several genotypically different strains. 
 
The ability of pneumococci to inhibit deposition of the complement protein C3 on 
the bacterial surface was found to depend on the capsular serotype as well as on 
other features of the bacteria. The results suggest that pneumococcal histidine triad 
(Pht) proteins may play a role in complement inhibition, but their contribution 
depends on the bacterial genotype. The capsular serotype was found to influence 
complement resistance more than the bacterial genotype. A higher concentration of 
anticapsular antibodies was required for the opsonophagocytic killing of serotypes 
resistant to C3 deposition. The invasive serotypes were more resistant to C3 
deposition than the opportunistic serotypes, suggesting that the former are better 
adapted to resist immune mechanisms controlling the development of invasive 
disease. The different susceptibilities of serotypes to complement deposition, 
opsonophagocytosis, and resultant antibody-mediated protection should be taken 
into account when guidelines for serological correlates for vaccine efficacy 
evaluations are made. The results of this thesis suggest that antibodies in higher 
quantity or quality are needed for efficient protection against the invasive serotypes. 
 
Keywords: pneumococcus, complement, opsonophagocytosis, capsule 
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Streptococcus pneumoniae (pneumokokki) on ihmisen nenänielussa esiintyvä bak-
teeri, jonka kantajista vain pienellä osalla ilmenee kliinisiä oireita. Pneumokokki on 
kuitenkin niin yleinen ihmisväestön keskuudessa, että sen aiheuttama tautitaakka on 
merkittävä. Vakaviin pneumokokkitauteihin (keuhkokuume, verenmyrkytys ja aivo-
kalvontulehdus) menehtyy vuosittain yli miljoona lasta. Invasiivisessa taudissa 
pneumokokki leviää verenkierron kautta normaalisti steriileihin ruumiinosiin. Kan-
tajuuden mahdollinen eteneminen taudiksi riippuu sekä pneumokokkikannan että 
isännän immuunipuolustuksen ominaisuuksista. Bakteeria ympäröivä polysakka-
ridikapseli on yksi tärkeimmistä pneumokokin taudinaiheuttamiskykyyn vaikutta-
vista tekijöistä. Kapseli suojaa bakteeria solusyönniltä ja voi vaikuttaa myös hengi-
tysteiden pintasolukkoon kiinnittymiseen. S. pneumoniae lajina sisältää yli 90 
erilaista kapseliserotyyppiä, joiden yleisyys taudinaiheuttajana vaihtelee. ”Invasiivi-
set” serotyypit ovat harvoin kannettuja, mutta aiheuttavat suhteellisen usein vakavia 
tauteja. Serotyypit, joita kannetaan oireettomasti pitkiä aikoja voivat aiheuttaa taudin 
henkilöillä, joiden immuunipuolustus on heikentynyt.  
 
Komplementti koostuu joukosta veressä ja solujen pinnoilla esiintyviä proteiineja. 
Sillä on keskeinen merkitys elimistön puolustuksessa taudinaiheuttajia vastaan. 
Valkosolut, jotka ilmentävät pinnallaan erityisiä reseptoreja, tunnistavat ja nielaise-
vat komplementtiproteiineilla päällystetyt pneumokokkisolut estäen näin bakteerin 
leviämisen elimistössä. Pneumokokin taudinaiheuttamiskyvyn kannalta on ratkaise-
vaa, että se kykenee suojautumaan synnynnäiseltä immuunipuolustukselta. Kapselin 
serotyyppi, virulenssiproteiinit sekä kannan genotyyppi, eli ainutlaatuinen geenien 
yhdistelmä, vaikuttavat pneumokokin kykyyn vastustaa komplementtia ja aiheuttaa 
tautia. Rokotuksen seurauksena elimistö tuottaa komplementin kertymistä ja solu-
syöntiä tehostavia vasta-aineita. Vuonna 2010 kansalliseen rokotusohjelmaan sisäl-
lytetty pneumokokkirokote kattaa yleisimmät vakavia tauteja aiheuttavat serotyypit. 
Tutkimusten perusteella rokotteen suoja välikorvantulehdusta ja mahdollisesti myös 
invasiivista tautia vastaan vaihtelee olennaisesti serotyypistä riippuen, toistaiseksi 
tuntemattomista syistä. 
 
Tämän väitöskirjatutkimuksen tavoitteena on arvioida pneumokokin kapselin ja 
virulenssiproteiinien merkitystä bakteerin kyvylle suojautua komplementilta ja solu-
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syönniltä. Keskeisin kysymys on selvittää, ovatko serotyyppien välillä havaitut erot 
taudinaiheuttamiskyvyssä seurausta niiden erilaisesta komplementin vastustusky-
vystä. On mahdollista, että virulenssitekijöiden merkitys pneumokokin kyvylle 
vastustaa komplementtia riippuu myös kyseisen bakteerikannan genotyypistä. 
Aiemmissa tutkimuksissa kapselin ja virulenssiproteiinien merkitystä komple-
mentin vastustuskyvylle on arvioitu vertaamalla vain yhtä tai muutamaa pneumo-
kokkikantaa. Tässä väitöskirjatyössä pneumokokin virulenssitekijöiden vaikutusta 
komplementin vastustuskyvylle selvitettiin tutkimalla virulenssitekijöiden merkitys-
tä useissa genotyypiltään erilaisissa bakteerikannoissa.  
 
Tutkimuksessa havaittiin pneumokokin kyvyn vastustaa komplementtiproteiinin C3 
kertymistä bakteerin pinnalle riippuvan sekä kapseliserotyypistä että bakteerikannan 
genotyypistä. Pneumokokin pintaproteiinien (histidine triad, Pht) todettiin vaikutta-
van komplementin vastustuskykyyn, mutta niiden merkitys riippuu todennäköisesti 
kannan genotyypistä. Tulokset osoittavat pneumokokin kapseliserotyypin olevan tär-
kein komplementin vastustuskykyyn vaikuttava tekijä. Kapseliserotyypillä havaittiin 
olevan merkittävämpi vaikutus kuin kannan genotyypillä. Komplementille vastus-
tuskykyisten serotyyppien tappoon tarvittiin korkeampi pitoisuus kapselivasta-
aineita. Nämä havainnot viittaavat siihen, että invasiiviset serotyypit ovat oppor-
tunistisia serotyyppejä sopeutuneempia vastustamaan immuunipuolustuksen keinoja 
rajoittaa invasiivista tautia. Serotyyppien väliset erot herkkyydessä komplementille 
ja solusyönnille tulisi huomioida rokotteiden tehoa arvioitaessa ja serologisia korre-
laatteja koskevia ohjeita laadittaessa. Tämän väitöskirjatyön tulosten perusteella 
vastustuskykyisiltä serotyyppeiltä suojautumiseksi rokotteiden tulisi tuottaa kor-
keampi vasta-aineiden pitoisuus tai laadullisesti tehokkaampia vasta-aineita. 
 
Avainsanat: pneumokokki, komplementti, fagosytoosi, kapseli 
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Streptococcus pneumoniae (pneumokock) är en bakterie som trivs i människans näs-
svalgrum. Pneumokocken orsakar kliniska symptom bara hos en liten del av dess 
bärare, men pneumokockens prevalens i människopopulationen är så hög att den ger 
upphov till en tung sjukdomsbörda. Globalt sett är S. pneumoniae den viktigaste 
bakteriella orsaken till blodförgiftning och lung- och hjärnhinneinflammation. Varje 
år avlider över 1 miljon barn till följd av pneumokocksjukdomar. Vid invasiv sjuk-
dom sprids bakterien via blodcirkulationen till normalt sterila vävnader. Risken för 
att bärare av pneumokocker insjuknar beror på egenskaper i såväl bakteriestammen 
som i värdens immunförsvar. Polysackaridkapseln som omger bakterien är en av de 
viktigaste faktorerna som påverkar pneumokockens förmåga att orsaka sjukdom. 
Kapseln skyddar pneumokocken mot fagocytos och kan hjälpa den att fästa sig på 
slemhinnan. S. pneumoniae som art omfattar över 90 olika kapselserotyper, men alla 
är inte lika vanliga som sjukdomsalstrare. “Invasiva” serotyper förekommer sällan 
hos bärare, men de ger relativt ofta upphov till allvarliga sjukdomar. Serotyper som 
symptomfritt finns hos bäraren kan orsaka sjukdom hos patienter med nedsatt 
immunförsvar.  
 
Komplementsystemet består av en grupp proteiner som uppträder i blodet och på 
cellytor. Det har en central roll i försvaret mot sjukdomsalstrarna. Leukocyter, som 
uttrycker vissa receptorer på sin yta, känner igen och sväljer pneumokockceller be-
lagda med komplementproteiner och på det sättet förhindrar de att bakterien sprids i 
kroppen. Pneumokockernas förmåga att skydda sig mot det medfödda immun-
försvaret är avgörande för deras förmåga att orsaka sjukdom. Kapselserotypen, 
virulensproteiner och stammens genotyp, dvs. den unika kombinationen av gener, 
påverkar pneumokockens förmåga att motstå komplementet och orsaka sjukdom. 
Vaccination stimulerar kroppen att producera antikroppar som främjar deposition av 
komplement och fagocytos. Pneumokockvaccinet som inkluderades i det nationella 
vaccinationsprogrammet år 2010 omfattar de vanligaste serotyperna som orsakar 
allvarliga sjukdomar. Kliniska undersökningar visar att vaccinets skydd mot mellan-
öreinflammation och möjligtvis också mot invasiv sjukdom beror på serotypen, av 
hittills okända orsaker. 
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Syftet med denna doktorsavhandling är att bedöma virulensproteinernas och 
kapselns betydelse för pneumokockens förmåga att skydda sig mot komplementet 
och fagocytos. Den centrala frågan är att utreda om skillnaderna mellan serotypernas 
förmåga att orsaka sjukdomar är en följd av att de har olika motståndskraft mot 
komplementet. Det är möjligt att olika virulensfaktorers relevans för pneumo-
kockens förmåga att orsaka sjukdomar också beror på bakteriestammens genotyp. I 
tidigare forskning har kapselns och virulensproteinernas inverkan på pneumo-
kockens resistens mot komplementet bedömts genom jämförelse av endast en eller 
några bakteriestammar. I denna undersökning görs en jämförelse mellan flera geno-
typiskt olika bakteriestammar för att utreda hur pneumokockens virulensfaktorer 
inverkar på bakteriens resistens mot komplementet. 
 
Pneumokockens förmåga att förhindra att komplementproteinet C3 samlas på 
bakteriens yta beror enligt undersökningen både på kapselserotypen och på 
bakteriestammens genotyp. Resultatet visar att vissa av pneumokockens ytproteiner 
(histidine triad, Pht) påverkar motståndskraften mot komplementet, men deras 
påverkan beror på bakteriens genotyp. Enligt resultatet är kapselserotypen den 
viktigaste faktorn som påverkar resistensen mot komplementet; den har en större 
inverkan än bakteriestammens genotyp. I fråga om serotyper som är resistenta mot 
komplementet krävdes det en högre halt av antikroppar mot kapselpolysackarider för 
fagocytos. Dessa observationer tyder på att invasiva serotyper har anpassat sig bättre 
än opportunistiska serotyper för att motstå immunförsvarets mekanismer som 
kontrollerar invasiva infektioner. Skillnaderna mellan olika serotyper beträffande 
sensitiviteten till komplementet och fagocytosen borde beaktas vid bedömningen av 
vaccinernas effektivitet och utarbetandet av anvisningar om serologiska korrelat. 
Enligt resultatet av denna doktorsavhandling bör vaccin producera en högre halt av 
antikroppar eller kvalitativt effektivare antikroppar. 
 
Nyckelord: pneumokock, komplement, fagocytos, kapsel
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IPD   invasive pneumococcal disease 
kDa   kilodalton 
KTL    Kansanterveyslaitos 
LytA   major pneumococcal autolysin 
mAb   monoclonal antibody 
MAC   membrane attack complex 
MASP   MBL-associated serine proteases 
MBL   mannose-binding lectin 
MLST   multi-locus sequence type 
MOPA   multiplex opsonophagocytic assay 
N/A   not applicable 
NanA   pneumococcal neuraminidase A 
ND   no data 
NET   neutrophil extracellular trap 
NHS   normal human serum 
NMS   normal mouse serum 
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OD    optical density 
OPA   opsonophagocytic assay 
PAMP   pathogen-associated molecular patterns  
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PCV   pneumococcal conjugate vaccine 
Pht   pneumococcal histidine triad protein 
pIgR   polymeric immunoglobulin receptor 
PRR   pattern recognition receptor  
PS   polysaccharide 
PsaA   pneumococcal surface adhesin A 
PspA    pneumococcal surface protein A 
PspC   pneumococcal surface protein C 
sIgA   secretory immunoglobulin A 
SC   secretory component 
SIGN-R1   ICAM-grabbing nonintegrin R1  
Th   T helper cell 
THYE   Todd-Hewitt broth supplemented with 5 % yeast extract 
THL   National Institute for Health and Welfare 
TLR   Toll-like receptor  
USA   United States of America 
WHO   World Health Organization 
wt   wild-type 
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1 INTRODUCTION 
Streptococcus pneumoniae is a gram-positive bacterium that colonizes the upper 
respiratory tract of healthy individuals. Occasionally, it breaks from its carriage 
habitat and causes infections ranging from acute otitis media to more severe diseases 
such as pneumonia, sepsis, and meningitis. S. pneumoniae is a heterogeneous 
species and it is divided into over 90 serotypes based on the structure of its capsular 
polysaccharide. The chemical structure of the polysaccharide capsule is a major 
determinant of pneumococcal virulence, as only a limited number of the serotypes 
accounts for the majority of invasive infections. Yet, clones sharing the same 
capsular serotype may have different abilities to cause disease, suggesting that other 
factors also contribute to their virulence.  
 
The human complement system is an essential part of the innate immune system, our 
first line of defense against invading microbes. It can rapidly recognize and opsonize 
invading bacteria for phagocytosis. However, successful bacterial pathogens have in 
turn evolved ingenious strategies to overcome this part of the immune system. The 
ability of S. pneumoniae to evade complement attack is probably one of the key 
factors contributing to its pathogenicity. The thick gram-positive cell wall protects 
the bacterium from direct complement lysis, whereas a polysaccharide capsule 
shields it from phagocytosis by inhibiting complement deposition on the capsule and 
recognition of complement deposited on the bacterial cell wall. In addition to the 
capsular type itself, the combination of the capsule and other virulence factors of the 
pneumococcal strain accounts for pneumococcal virulence. Several pneumococcal 
virulence proteins have been found to act by inhibiting complement.  
 
The purpose of this thesis is to assess the relative contribution of different 
pneumococcal virulence factors to the complement resistance of the bacterium. One 
of the questions is whether differences between pneumococcal serotypes to resist 
complement explain the different abilities of serotypes to cause disease. In addition, 
the potential function of a pneumococcal surface protein in complement inhibition in 
different genotypes was studied. By identifying factors and mechanisms whereby 
pneumococcus evades complement we will better understand how the microbe 
causes disease and how vaccines consisting of pneumococcal virulence factors could 
prevent it. 
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2 REVIEW OF THE LITERATURE 
2.1 Pneumococcal carriage and disease 
2.1.1 Exposure and colonization 
Pneumococcus is a common component of the microbiota of the human upper 
respiratory tract. There are over 90 serologically distinct pneumococcal capsular 
serotypes. All of them are able to establish a carrier stage in humans. Variability in 
the colonization efficiency may exist since some serotypes are carried more 
frequently than others (38). The serotype affects nearly every aspect of 
pneumococcal pathogenesis as well as the nasopharyngeal carriage, which precedes 
disease and provides the reservoir for transmission of the organism (38).  
 
Most children acquire pneumococcus in their nasopharynx during the first years of 
life, but the acquisition age and carriage rates vary by geographic location and 
population (113). The rate of acquisition is much slower in industrialized countries 
than in developing countries. At the age of two months, 9% of Finnish children are 
colonized by pneumococcus, and by the age of two years, the proportion of carriers is 
43% (353). In The Gambia, 80% of infants carry pneumococcus by the age of two 
months (149). In Papua New Guinea all infants become carriers by the age of three 
months (246) whereas in Bangladesh the proportion of carriers at the age of four 
months is 50% (126). The prevalence of carriage increases during the first months of 
life. It starts to decrease after the age range of three to five years. The average 
carriage rates in different populations range from 40 to 50% in children and 20 to 
30% in adults (114). In Finland, the frequency of carriage is only 3% in the adult 
family members of day-care children (208).  
 
Young children may be simultaneously colonized with multiple capsular serotypes, 
which promotes horizontal gene transfer events and may lead to capsule switching 
between pneumococcal strains (57). However, epidemiological data suggest that 
different pneumococcal serotypes (or strains) compete with each other in colonizing 
human hosts. Acquisition of new serotypes in already colonized hosts was found to 
be weak in Danish day-care children (14). The duration of carriage is age-dependent 
(151). The first carriage in children lasts most commonly from 2.5 to 4.5 months, and 
decreases with successive pneumococcal serotypes and with age (96, 127). Prolonged 
carriage is seldom associated with progressive disease; a pneumococcal disease has 
been suggested to be associated with recent pneumococcal acquisition, where 
infection occurs within one month of acquisition of a new serotype (127, 206, 353).  
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The duration of carriage varies by capsular serotype (342) and is inversely correlated 
with the attack rate of invasive pneumococcal disease (Fig. 1). Capsular serotypes, 
which are carried for a short period and have a high attack rate, behave like “primary 
pathogens”: they affect previously healthy individuals and are associated with lower 
mortality. Meanwhile, serotypes that are carried for a long time behave like 
opportunistic pathogens. They infect patients with an underlying predisposition and 
are associated with more severe disease and higher mortality (341). This observation 
correlates with population-based studies, in which the risk of death from invasive 
pneumococcal disease (138) and pneumonia (377) was reported to be higher for 
serotypes with a high prevalence in carriage and low invasiveness.  
 
 
 
Figure 1. Carriage duration and invasiveness of pneumococcal serotypes. The 
median duration of carriage for each serotype was estimated from interval swabbing 
of the nasopharynx in a carriage study of two Oxford birth cohorts. The invasive 
disease incidence data were derived from national United Kingdom data from 
children under 2 years. Correlation between the attack rate (the incidence of invasive 
pneumococcal disease, IPD, per incidence of pneumococcal acquisition) and duration 
of carriage for each capsular serotype was statistically significant (P<.0001). From 
(342). Reproduced with the permission of the copyright holder, Oxford University 
Press. 
 
THL 2011 – Research 58 19 
Interplay of Virulence Factors 
in Complement Resistance of 
Streptococcus pneumoniae 
 
2.1.2 Pneumococcal diseases 
Nasopharyngeal colonization precedes pneumococcal disease, but symptomatic 
disease occurs in only a small percentage of persons who are colonized. Sometimes 
pneumococci invade adjacent sites and/or invade the bloodstream, causing disease. 
The clinical manifestations of pneumococcal infection can be classified into two 
major categories: invasive and mucosal infections. Mucosal infections of the middle-
ear, the respiratory tract and the lungs are the result of the direct spread of the 
organism from the nasopharynx. Invasive disease follows usually haematogenous 
spread to normally sterile tissues. Invasive disease can also result from local 
spreading of the bacteria, for example from the lung to the pleural space or from the 
paranasal sinuses to the central nervous system. By far the most common form of 
pneumococcal disease worldwide is bacteremic pneumonia, the next most common 
form being pneumococcal meningitis, followed in order of decreasing incidence by 
blood stream infection (or sepsis) and otitis media (252, 280).  
 
Acute otitis media (AOM) is a very common disease in industrialized countries 
among infants and young children, peaking during the age range of 6 to 18 months 
(188, 355).  Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella 
catarrhalis are the predominant bacteria associated with otitis media, with 
pneumococcus being the most common causative agent (188). The bacteriology of 
acute sinusitis is similar to that of otitis media, with S. pneumoniae and/or H. 
influenzae being isolated in the great majority of cases (129). Prior respiratory tract 
infection of viral origin enhances the adherence of pneumococcus to tracheal cells 
and progression towards pulmonary infection (128, 283). Worldwide, an estimated 
1.2 million people die of pneumococcal pneumonia each year (263). S. pneumoniae 
is considered to be the main cause of severe pneumonia among children and HIV-
infected patients in the developing world (193). Pneumococcal pneumonia is also the 
most common cause of death due to infectious diseases in industrialized countries, 
contributing to morbidity and mortality, especially among elderly patients (106). 
Invasive pneumococcal disease (IPD) is diagnosed by positive blood or 
cerebrospinal fluid cultures. Spread of bacteria from the infection site to the 
bloodstream is relatively common in pneumococcal pneumonia. A positive blood 
culture can only be obtained from a minority of patients with pneumococcal 
pneumonia (15 to 30% of cases) (254), although a higher number of positive blood 
samples (44%) could be detected with PCR (358). Pneumococcal meningitis causes 
~70,000 deaths annually, and other septic infections cause a similar number of deaths 
of young children in developing countries (263). Pneumococcal meningitis is 
associated with a higher mortality compared with other causative bacteria (22, 120), 
and neurological sequelae are common among those recovered (369, 391).  
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Pneumococcal infections affect specific risk groups. Conditions that increase the 
risk of serious pneumococcal disease are those that affect the immunological defense 
systems: reduced phagocytosis or ability to produce antibodies. Immaturity of the 
immune system in early life and waning immunity in the elderly predispose to 
pneumococcal diseases. Immunocompromising conditions include functional or 
anatomical asplenia, sickle cell disease, HIV, cigarette smoking, alcohol abuse, and 
the use of immunosuppressive drugs (61, 102, 196, 276, 294). Congenital 
deficiencies in the production of immunoglobulins increase the risk of developing 
pneumococcal infections (58). Individuals deficient in the early components of the 
classical or alternative pathway of complement have an increased susceptibility to 
recurrent pneumococcal infections (108, 168, 388). 
 
2.2 Host mechanisms of immune protection against  
S. pneumoniae 
 
The local host immunity has an important regulatory role in the trafficking of 
pathogens in the upper respiratory tract (113). A poor mucosal immune response 
might lead to persistent and recurrent colonization and consequent infection, whereas 
a brisk local immune response to the pathogen will eliminate colonization and 
prevent recolonization (114). In healthy individuals, the mucosal surfaces, with their 
epithelial cells and the secreted mucus, constitute a physical barrier that prevents 
pathogens from gaining access into deeper tissues. Once pneumococcus has crossed 
the first natural barriers of the host, it triggers activation of the host immune response 
(67). In the primary phase of infection, the innate immune defenses are of most 
importance, as induction of the antibody response takes time to develop. Antibody-
mediated protection is important in preventing subsequent infections.  
 
2.2.1 The complement system 
The complement system is the major humoral part of innate immunity. Killing of 
microorganisms is one of its main functions (319). The complement system 
constitutes a critical link between the innate and acquired immunity by regulating B-
cell- and T-cell-mediated immune responses (66). It consists of a series of proteins 
circulating in the blood and in tissue fluids. Many complement proteins occur in 
plasma as inactive enzyme precursors and some reside on cell surfaces. In response 
to the recognition of the molecular components of a microorganism, the complement 
proteins become sequentially activated, working in a cascade where the binding or 
activation of one protein promotes the binding or activation of the next protein in the 
cascade (199). The complement system can be activated through three different 
routes, triggered by various initiating proteins that recognize microbial ligands. 
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Classical pathway activation is initiated by C1q binding to Fc regions of antibodies 
on microbial surfaces, whereas the lectin pathway is activated directly by bacterial 
surface components in the absence of antibody-antigen complexes. The alternative 
pathway is initiated by the spontaneous hydrolysis of C3 and production of C3b, 
which can bind to pathogen (or host cell) surfaces. The pathways differ in the 
manner in which they are activated and ultimately produce key enzymes called C3 
convertases (Fig. 2). The assembly of the C3 convertases is a pivotal step in the 
complement pathway. These enzymes cleave the C3 complement component to 
result in microbe-bound C3b which, in addition to its inactivated iC3b form, can be 
recognized by leukocytes. 
 
2.2.2 The pathways of complement activation 
The binding of antibody to its target antigen initiates activation of the complement 
system through the classical pathway. C1q of the C1 complex binds to 
appropriately spaced Fc regions of immunoglobulin molecules. It is important for 
IgG molecules to achieve a critical density on the surface in order to engage C1q 
and activate the C1 complex. Human IgG subclasses differ in their ability to activate 
the alternative pathway of complement. In general, the subclasses activate 
complement in the order IgG3 > IgG1 > IgG2. Because IgM is pentameric and each 
target-bound IgM can bind a C1q molecule, IgM is a more potent activator of the 
classical pathway than IgG. Natural IgM, which has specificity for microbial surface 
antigens and arises without prior exposure to the microbe, has a critical role in the 
immediate defense against bacterial infection (37). The classical pathway is also 
activated when members of the pentraxin family (which includes C-reactive protein, 
serum amyloid P component, and pentraxin 3) bind to surfaces and engage C1q 
(255, 313, 396). Classical pathway activation can also be initiated by the binding of 
certain pneumococcal polysaccharides to the specific adhesion molecule, (ICAM-3)-
grabbing nonintegrin-related R1 (SIGN-R1), a lectin which is found in spleen 
macrophages (180). SIGN-R1 binds C1q directly, initiating the assembly of C3 
convertase without the traditional requirement for antibody (180). Also, 
lipopolysaccharides of gram-negative bacteria can activate the classical pathway 
independently of antibodies (219). The C1 complex is formed by the association of 
the recognition unit C1q with a Ca2+ -dependent catalytic subunit consisting of  C1s 
and C1r proteases (11). Formation of the C1 complex is followed by enzymatic 
cleavage of C4, resulting in exposure of an internal thioester bond in C4b (203), 
which can react readily with nucleophilic groups such as –OH to form an ester 
linkage or –NH2 to form an amide linkage (92). In the next step in classical pathway 
activation, C2 binds to C4b deposited on the surface and is cleaved into C2a (and 
C2b). The remaining C4bC2a is the C3 convertase of the classical pathway. 
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The lectin pathway is triggered by the interaction of microbial carbohydrates with 
mannose-binding lectin (MBL) in the plasma and tissue fluids. MBL binds to 
polysaccharides rich in mannose and N-acetyl glucosamine residues, which are 
present on some microbial cells (111). MBL is assembled from identical polypeptide 
chains and bears structural similarity to C1q (93). As with the C1 complex of the 
classical pathway, the lectin pathway also consists of recognition molecules such as 
MBL and the ficolins and catalytic proteins, which are MBL-associated serine 
proteases (MASP-1, MASP-2, MASP-3) (368). MASPs are homologs of C1r and 
C1s of the classical pathway. MASP-2 is the main initiator of the lectin complement 
pathway by cleaving C4 and C2 to form the C4bC2a complex leading to further 
downstream complement activation (357). 
 
The alternative pathway does not require initiation by antibodies and, thus, serves 
to protect the host from invading pathogens prior to the development of adaptive 
immunity. The alternative complement pathway is constitutively activated at low 
levels, but is only amplified when C3b binds to foreign surfaces. Spontaneous 
hydrolysis results in generation of an altered C3 molecule called C3(H2O) capable of 
binding factor B (199). Once factor B associates with C3(H2O), it undergoes a 
conformational change, which renders it susceptible to cleavage by the serine 
protease factor D, generating Ba and Bb (109, 210, 211). The Bb fragment remains 
attached to C3(H2O) and, through its own serine protease domain, can cleave the 
C3a fragment from C3 to yield C3b. Cleavage of C3 results in a conformational 
change in the molecule and exposure of its internal thioester bond. Like C4b of the 
classical pathway, C3b can bind to –OH and –NH2 groups on surfaces. Surface-
bound C3b can then bind factor B, generate more C3 convertases, and thus set into 
motion an amplification loop. 
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Figure 2. Complement activation pathways. Antibody-antigen complexes and 
CRP initiate activation of the classical pathway. Mannnose binding lectin (MBL) 
detects particular sugar units and activates the lectin pathway. The alternative 
pathway is activated by the binding of C3 to microbial surfaces. Activation initiated 
by any of the three pathways is further augmented by the activation of the alternative 
pathway: the amplification loop. Factor H (H) and C4b-binding protein (C4BP) act 
as cofactors for factor I (I)-mediated cleavage of C3b and C4b and dissociation of 
the C3 and C5 convertases. 
 
 
Complement activation by each pathway generates a C3 convertase, which cleaves 
soluble C3 into two fragments: the anaphylatoxin C3a and the opsonic fragment 
C3b. C3b undergoes a conformational change that results in the exposure and 
disruption of a thioester bond linking Cys988 and Glu990 (354). The reactive carbonyl 
group of Glu990 attaches to the acceptor surface in a covalent ester or amide linkage 
with exposed carboxyl groups or with free amino groups of tyrosine residues, 
respectively (158, 204, 324, 334). Exposure of the reactive carbonyl group enables 
covalent binding of C3b to polysaccharides, amino sugars, or peptides exposed on 
the cell wall (157). With the assistance of various cofactors, e.g. factor H, surface-
bound C3b is then sequentially processed, via the enzymatic activity of factor I, into 
smaller fragments (iC3b and C3d/C3dg). Importantly, C3b and its downstream 
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cleavage products remain covalently bound to the target surface and act as ligands 
for different complement receptors on phagocytic cells. 
 
The terminal pathway of complement activation leads to formation of a membrane 
attack complex (MAC), which inserts itself into cell membranes and can cause 
osmotic lysis of target cells. MAC formation is initiated by the cleavage of C5 to 
C5a and C5b by C5 convertases of the classical pathway (C4bC2aC3b) or the 
alternative pathway (C3bBbC3b). The terminal components of complement, C6-C9, 
will sequentially build on C5b to form a C5b-9 complex into the cell membrane, 
where binding of more C9 molecules results in pore formation (362, 363). 
 
2.2.3 Functions of the complement system 
The complement system contributes to the host’s defense against infection directly 
through its opsonic, inflammatory, and lytic activities and indirectly by enhancing 
antibody responses. Proteins produced by the complement pathways trigger 
inflammation (C3a, C5a, and C4a) and chemotactically attract phagocytes to the 
infection site (C5a). Formation of the terminal complex on the cell membrane causes 
lysis of gram-negative bacteria. Microbes sufficiently coated with C3 fragments are 
recognized by the different complement receptors (CRs) on various host phagocytes 
(Table 1). On the phagocytic cells, the CRs mediate attachment, engulfment, and 
killing of opsonized organisms (311). CR3 and CR4, expressed on neutrophils, 
monocytes, and macrophages, recognize iC3b, C3c, and C3dg molecules. They have 
high affinity for iC3b and lower affinity for C3b. CR1 is principally expressed on 
erythrocytes, monocytes, neutrophils, and B cells. It serves as the main system for 
the processing and clearance of complement-opsonized immune complexes. In 
contrast to CR3 and CR4, CR1 has high affinity for C3b and lower affinity for iC3b 
(32, 197), and it also binds C1q and C4b (192). CR1 mediates immune adherence 
and attachment to phagocytes, but is much less effective than CR3 and CR4 in 
promoting phagocytosis (122). Because CR1 has cofactor activity, it participates 
directly in complement activation by facilitating the factor I-mediated conversion of 
C3b to iC3b. This action of CR1 can down-regulate further complement activation 
(160). CR2 is a nonphagocytic receptor that binds C3dg and C3d and thereby 
influences activation and antibody production by B cells (88, 245). CRIg is found on 
macrophages residing in tissues, and it participates with CR3 in the removal of 
particles opsonized with C3b and iC3b from circulation (146). 
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Table 1. Complement receptors (CRs)  
CR CD proteins(s) Main CR expressing cell types Ligand(s) 
CR1 CD35 Erythrocytes, Phagocytes C3b, C4b 
CR2 CD21 B lymphocytes C3dg, C3d 
CR3 CD11b/CD18 Phagocytes iC3b 
CR4 CD11c/CD18 Phagocytes iC3b 
CRIg  Tissue macrophages C3b, iC3b 
Adapted from Siber et al. 2008 (333). 
 
2.2.4 Regulation of complement activation 
To avoid overconsumption of and attack against host cells, while targeting microbial 
surfaces, the complement activation needs to be tightly regulated. This regulation 
occurs via both soluble (factor I, factor H, factor H-like protein 1 (FHL-1)), C4b-
binding protein (C4BP)) and membrane-bound (CRIg, CD35, CD46, CD55, and 
CD59) complement regulatory proteins (Fig. 2). 
 
Factor H is a plasma glycoprotein involved in the down-regulation of complement 
activation (240). Factor H controls complement activation on self cells by regulating 
the alternative pathway of complement activation in the fluid phase as well as on 
host cellular surfaces. Factor H binds to and inactivates C3b by serving as a cofactor 
for cleavage of C3b by factor I, dissociating the alternative pathway C3 convertase 
and by competing with factor B for binding to C3b (273, 375). The cleavage of C3b 
by factor I generates iC3b, C3dg, and C3d. If these molecules are attached to a 
microbial surface, they remain covalently attached to the organism and serve as 
ligands for complement receptors.  
 
C4BP is a plasma protein that inhibits both the classical and lectin pathways of 
complement by acting as a cofactor for factor I-mediated degradation of C4b. It also 
accelerates the decay of the classical pathway C3 convertase (36). In addition, C4BP 
is a cofactor for factor I in the cleavage of C3b and may down-regulate the 
alternative pathway (35). 
 
2.2.5 The role of complement in immune defense against pneumococci 
The complement system is one of the most essential components of host defense 
against pneumococcus, which is shown by the severe infections suffered by 
individuals with complement deficiencies. Depletion of both alternative and 
classical pathways resulted in a lethal defect of intravascular clearance of bacteremic 
pneumococcal infection in a guinea pig model (154). In a murine colonization 
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model, C3-deficient mice lacking a functional complement system cleared 
pneumococcal colonization at the same rate as wild-type mice (370). In another 
study, nasopharyngeal colonization density was similar in complement-depleted and 
control mice, but in contrast to control mice, which remained healthy, the majority 
of complement-depleted mice developed sepsis (40). Until stable colonization is 
established, pneumococci reside in the luminal mucus (258), whereas the activities 
of phagocytic cells (macrophages as well as neutrophils) are likely to be confined to 
the tissues rather than taking place in the lumen (241). As most secretions are 
hypotonic, phagocytes probably do not survive with functional activity for long in 
the bulk fluid phase. However, the microenvironment close to the mucosal surface 
may permit phagocytic activity, as in the case of alveolar macrophages (241).  
 
Alveolar type II epithelial cells and alveolar macrophages are known to synthesize 
and secrete complement proteins locally (72, 352, 373). Although local complement 
sources contribute relatively little to the total complement pool, which is mostly 
synthesized by the liver hepatocytes (72), a local source of complement along the 
alveolar epithelium may provide an important early clearance mechanism for 
pneumococci before immune cells are recruited and systemic complement can reach 
the lung. The concentrations of complement components present in mucosal 
secretions are usually well below those found in serum, and it is uncertain whether 
the classical or alternative complement pathway operates as a fully functional 
system in secretions (241, 373). Complement plays an important role in innate 
immune defense during the initial hours of pneumococcal infection within the lungs 
(184), where C3 probably acts as an opsonin for resident alveolar macrophages. 
Depletion of neutrophil-like cells did not increase the risk of sepsis in colonized 
mice, which implies a neutrophil-independent role for complement, specifically C3, 
in the prevention of a pneumococcal invasion following colonization by the rapid 
killing of invading bacteria (40). Development of otitis media and bacteremia in a 
chinchilla model was related to the ability of pneumococcal strains to resist C3 
deposition, whereas the density of nasopharyngeal colonization was independent of 
the susceptibility of the strains to complement (322). However, all animal 
experiments with pneumococci need to be interpreted with caution because of the 
specificity of pneumococcus to humans.  
 
Antibody to capsular polysaccharides or surface proteins of S. pneumoniae initiates 
the activation of the classical pathway by binding complement protein C1q on the Fc 
portion of IgG or IgM. The classical pathway can be activated not only by specific 
anti-pneumococcal antibodies, but with natural IgM (53, 404) and serum proteins 
detecting pathogen-associated structures and interacting with C1q (180, 400). The 
alternative pathway is activated even in the absence of adaptive immunity by the 
direct binding of C3b on the bacterial surface, but most importantly the alternative 
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pathway is responsible for augmenting C3b deposition (53). Amplification of 
complement activation by the alternative pathway is also essential when the 
activation has been initiated via the classical pathway (365). The classical pathway 
is considered the dominant pathway of complement activation in pneumococcal 
infection, because inhibition of the classical pathway, but not the alternative 
pathway, results in significantly reduced deposition of C3b on the bacterium (53). 
The lectin pathway was suggested to play only a minor role in complement 
activation in pneumococcal infection, because in a mouse model, the MBL pathway 
contributed little toward C3b deposition (53). In line with this finding, genetic MBL 
deficiency was found to be associated with only a small increase in susceptibility to 
pneumococcal disease in humans (314). However, in a study of African children 
with invasive pneumococcal disease, the authors found an association between 
infection by low invasive serotypes and certain common genotypes with MBL 
deficiency (367). Since pneumococcus has a thick gram-positive cell wall, it is 
resistant to direct complement lysis. The main function of complement in 
pneumococcal infection is opsonization of the bacterial surface with the C3 
degradation products C3b and iC3b, which enables the intake of pneumococci by 
phagocytic cells with the help of complement receptors (105, 123, 312). 
Complement receptors CR1, CR2, CR3, and CR4 all play important roles in host 
defense against pneumococcal infection (296).  
 
2.2.6 The humoral immune response to pneumococcus 
Mucosal immunity has an important local regulatory role in the upper respiratory tract 
(113). In general, mucosal immunity matures earlier than systemic immunity, and is 
present from the age of 6 months (114). IgA, the major class of Ig in secretions, 
classically functions by interfering with microbial attachment to host tissues by 
binding to adhesion proteins on the bacterial surface (69). IgG and secretory IgA 
antibodies directed against capsular polysaccharides and surface-associated proteins 
have been observed in the saliva of children in response to colonization by S. 
pneumoniae (336, 337). Colonization also stimulates the production of systemic IgG 
responses to capsular polysaccharides and surface antigens such as pneumococcal 
surface adhesin A (PsaA), pneumococcal surface protein A (PspA), pneumococcal 
surface protein C (PspC), pneumococcal histidine triad proteins (Phts), and 
pneumolysin (239, 293, 335, 346). Increased concentrations of serotype-specific 
antibodies against pneumococcal polysaccharides have been correlated with increased 
protection against carriage of a few common serotypes (121, 376), and antibodies 
against PspA in saliva have been associated with a decreased risk of acute otitis media 
(339). Pneumococcal carriage in a mouse model induced the production of mucosal 
IgA and systemic IgM in response to the capsular polysaccharide and IgG against 
PspA, which increased over time and correlated to reduced nasopharyngeal 
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pneumococcal numbers (300). Concentrations of serum antibodies to several 
pneumococcal surface proteins have been shown to increase during invasive infection 
(2, 215). Bacteremic infection incidence ordinarily peaks within the first 6 to 12 
months of life and is thought to reflect the absence of type-specific anticapsular 
antibodies from the serum of young infants. However, susceptibility of adult 
volunteers to pneumococcal carriage correlated with serum IgG to PspA, but not with 
antibody to the homotypic capsular polysaccharide providing evidence for the role of 
antibody to this protein in preventing pneumococcal carriage by humans (237).  
 
2.2.7 Cell-mediated immunity in pneumococcal infection 
Although antibodies have been shown in multiple experiments to mediate protection 
against pneumococcal disease (217), the mechanisms of protection against 
colonization may be quite different from those involved in invasive pneumococcal 
disease. The decrease in the prevalence of pneumococcal carriage with increasing 
age beyond early childhood occurs in a largely serotype-independent manner (217). 
This suggests that the development of serotype-specific antibodies is not the only 
mechanism of immunity. The cellular compartment of immunity has been proposed 
to be the main effector in protection against colonization (229). The adaptive 
cellular immune response at mucosal surfaces to invading respiratory pathogens is 
based on the presence of antigen-specific CD4+ T lymphocytes. The significance of 
CD4+ T cells in clearance of pneumococcal colonization is supported by clinical 
findings. HIV infection is associated with a significantly increased risk of 
colonization and reduced time to new colonization (118). The increased risk of 
pneumococcal infection in HIV positive patients is inversely related to CD4+ T cell 
count (94, 117). The main populations of effector CD4+ T cells are type 1 T helper 
(Th1), type 2 Th (Th2), and type 17 Th (Th17) cells, typically producing interferon 
(IFN)-, interleukin (IL)-4, and IL-17, respectively. In a pneumococcal colonization 
model of mice, the clearance of bacteria from the nasopharynx required CD4+ T 
cells and was independent of serotype-specific antibodies (232) or antibody to 
protein antigens, although the concentrations of antibodies to PspA and PsaA 
correlated with protection against colonization (359). Antigen-specific T-cell 
immunity, in the absence of antibodies, has been shown to be sufficient for 
protection against pneumococcal colonization in mice (361).  
 
Pathogen-associated molecular patterns (PAMPs) are typically conserved structures 
found among microbes (277). These microbial components are recognized by Toll-
like receptors (TLRs) and other pattern recognition receptors (PRRs) expressed by 
cells of the innate immune system such as macrophages and dendritic cells (181, 
198). TLR2 recognizes pneumococcal lipoteichoic acid and cell wall peptidoglycan 
(277), whereas TLR4 interacts with pneumolysin (230). Detection of pneumococci 
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by pattern recognition receptors initiates release of chemokines and cytokines, 
resulting in the recruitment and activation of leukocytes (277). TLR2 knock-out 
mice displayed increased disease severity in a pneumococcal meningitis model (95) 
and impaired clearance in a nasopharyngeal colonization model compared with 
wild-type mice (370). In murine pneumococcal pneumonia, TLR2 had only a 
modest contribution to the host response (195). Recognition of pneumolysin by 
TLR4 has been shown to have an inflammatory effect on macrophages in vitro 
(230). The role of TLR4 in pneumococcal infections appears to be localized to the 
airway surfaces, as the absence of TLR4 made no difference to survival rates and 
blood bacterial counts after intravenous infection of mice (27). However, in 
pneumococcal pneumonia, TLR4 mutant mice showed a reduced survival (42). 
 
2.2.8 Opsonophagocytosis  
Neutrophils, the most abundant group of leukocytes found in peripheral blood, are the 
most important effector cells mediating the opsonophagocytic clearance of 
pneumococci from circulation. Fc receptors, which detect antibodies bound to 
pneumococcal surface antigens, mediate neutrophil phagocytosis to some degree 
(323). However, opsonophagocytic killing of pneumococci is more strongly 
dependent on complement activation and phagocytosis mediated by complement 
receptors than direct antibody-mediated phagocytosis (323). Compared to the rate of 
phagocytosis in the presence of antibody alone, opsonophagocytosis of serotype 3 
pneumococcus was accelerated sevenfold by the addition of complement proteins in 
fresh human serum (371). Opsonization with antibodies (IgG and IgM) that enhance 
deposition of opsonic C3 molecules is especially important in host protection against 
invasive pneumococcal infections. The standardized opsonophagocytic assay (OPA) 
measures the ability of antibodies to enhance the phagocytosis of encapsulated 
pneumococci (308). The in vitro opsonophagocytic activities of serum antibodies are 
believed to represent the functional activities of the antibodies in vivo and, thus, to 
correlate with protective immunity (175). Serum samples in which the levels of 
antibodies to capsular polysaccharides have increased after pneumococcal carriage 
often have opsonophagocytic activity against the homologous serotype (345).  
 
It has been demonstrated in murine models that pneumococcal colonization of the 
upper respiratory tract triggers an acute inflammatory response characterized by a 
robust influx of neutrophils into the lumen of the paranasal spaces (258, 370). Data 
from a co-colonization mouse model (of S. pneumoniae and H. influenzae) suggest 
that successful clearance of pneumococci from the nasopharynx results from 
opsonization by complement, followed by phagocytosis by neutrophils, which are 
recruited to the mucosal surface (225). Alveolar macrophages are the first cells that 
combat pneumococci during early pneumonia (125) and the main cell population 
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that mediates mucosal responses in the lower airways. Alveolar macrophage 
phagocytosis of pneumococci and the clearance of bacteria from the lungs are 
enhanced by opsonization of bacteria with IgG and/or complement (124).  
The acute inflammatory response may be ineffective in controlling the initial 
mucosal colonization (258), but it may however enhance the adaptive immune 
response and subsequent bacterial clearance (235). Prior exposure to live bacteria or 
intranasal immunization by killed pneumococcal whole cell antigen was found to 
confer protection in mice via interleukin 17A (IL-17A) produced by a subset of 
CD4+ T cells, so called Th17 cells (222). IL-17A-mediated protection against 
pneumococcal colonization results in the recruitment of neutrophils into the upper-
airway lumen to clear bacteria, which has been found to occur both in the absence 
and in the presence of antibodies and complement (222, 407). TLR2-dependent 
activation of Th17 cells results in the recruitment of macrophages (during primary 
and secondary colonization) and neutrophils (during secondary colonization) into 
the upper airways of mice and subsequent clearance of pneumococci from the 
mucosal surface (407). Depletion of either IL-17A or CD4+ T cells was shown to 
block the recruitment of phagocytes required for the effective clearance of 
pneumococcal colonization (407).  
 
2.3 Virulence factors involved in adhesion and early 
pathogenesis 
 
Colonization of mucosal surfaces by pneumococcus is often a transient process, but 
it may also be an initial event in the progression to disease. A number of 
pneumococcal proteins are believed to promote colonization of the nasopharynx. 
Pneumococcus produces up to three different neuraminidase enzymes, NanA, NanB, 
and NanC, which cleave terminal sialic acids from host glycolipids and 
gangliosides, revealing new receptors for adherence or invasion (29, 64). NanA is 
the most strongly expressed neuraminidase and has a crucial role in biofilm 
production (275). Direct adhesive properties have been demonstrated in particular 
for PspC and pneumoccal pili-like appendages. Pneumococcal major autolysin 
(LytA) is a cell wall hydrolase, which degrades the peptidoglycan layer and is thus 
responsible for cell lysis under conditions in which biosynthesis stops, such as 
nutrient starvation or when the bacteria are treated with antibiotics (112). Many of 
the pneumococcal virulence factors have dual functions and contribute to both 
colonization and virulence in invasive disease (Table 2). 
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Table 2. Pneumococcal virulence factors 
Virulence factor Virulence functions References 
Neuraminidase  Reveales receptors for adherence by cleaving 
terminal sialic acids from the resiratory 
mucosa. 
(29, 64) 
Autolysin Digests the bacterial cell wall and thereby 
releases inflammatory cell wall components. 
(21, 112) 
IgA1 protease Cleaves human IgA1, which prevents 
antibodies from inhibiting adhesion. 
(186, 285, 
381) 
Pneumococcal 
surface adhesin A 
Aids binding to human epithelial cells. (8, 31) 
Pneumococcal 
surface protein A 
Binds apolactoferrin, which may help in the 
acquisition of iron on mucosal surfaces. 
Inhibits complement C3 deposition. 
(130, 133, 
213, 296) 
  
Pneumococcal 
surface protein C 
Promotes adhesion to and translocation across 
epithelial layers. Inhibits complement C3 
deposition. 
(4, 132, 134, 
169, 170, 292, 
310, 405) 
Pneumolysin A multifactorial cytotoxin, which enhances 
inflammation and activates and consumes 
complement at a distance from the pathogen. 
(234, 401) 
Pili Mediate adherence to respiratory epithelium. (19, 23) 
Capsule Promotes colonization by helping the 
bacterium to escape from mucosal secretions 
to the epithelial surface. Protects from 
phagocytosis. 
(162, 258) 
Pneumococcal 
histidine triad 
proteins 
Inhibits complement C3 deposition. (269) 
This list is not exhaustive and only selected examples are shown. For detailed 
descriptions of virulence factors, see the main text. 
 
2.3.1 IgA1 protease 
Pneumococcus possesses three large extracellular or surface-associated zinc-
metalloproteinases, which are IgA1 protease, ZmpB, and ZmpC, which probably 
have different roles in the virulence of the bacterium (68). The mainly surface-
associated IgA1 protease (Fig. 3) is known to specifically cleave the hinge region of 
human IgA1, the predominant class of immunoglobulin present on mucosal 
membranes (307). The cleavage of bound IgA1 produces bacterial surface antigens 
that are bound to Fab fragments, which prevents inflammation from being initiated 
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through host recognition of the Fc region of the antibody. IgA1 protease is important 
for the ability of pneumococcus to colonize mucosal membranes in the presence of 
secretory IgA antibodies (186, 285). Cleavage of serotype-specific IgA1 was shown 
to markedly enhance bacterial attachment to host cells (381). It appears that IgA1 
protease has a dual role, which, on one hand, overcomes the inhibitory action of 
mucosal antibodies and, on the other, promotes adherence because bound Fab 
fragments may neutralize the inhibitory effect of negatively charged capsules upon 
adhesive interaction with host cells, allowing pneumococci to persist in the 
respiratory tract for extended periods (381). IgA1 protease is found in almost all 
clinical pneumococcal isolates, but the considerable antigenic heterogeneity of the 
protein renders it less attractive as a potential component of future vaccines (218). 
 
2.3.2 Pneumococcal surface adhesin (PsaA) 
Pneumococcal surface antigen A (PsaA) is a lipoprotein member of an ATP-binding 
cassette (ABC) transporter complex, which functions to transport manganese (90, 
260). PsaA is a conserved antigen, which is present in all examined S. pneumoniae 
strains representing different capsular serotypes (248, 325). Mutations in PsaA have 
been shown to cause pleiotropic effects and reduce virulence in multiple infection 
models (31, 90, 233, 364). The role of PsaA as a potential pneumococcal adhesin 
was first demonstrated by the low adherence of the PsaA-deficient mutant to 
pneumocytes (31). Later, it was reported that PsaA-deficient mutants failed to 
adhere to human nasopharyngeal epithelial cells, and that antibodies to PsaA could 
inhibit the adhesion of wild-type pneumococci to the cells (309). PsaA is closely 
associated with the bacterial surface (Fig. 3), and it is assumed that the protein is 
exposed on the pneumococcal surface during carriage, when the capsule is relatively 
thin (205). E-cadherin was identified as the receptor for PsaA on human epithelial 
cells (8). 
 
2.3.3 Pneumococcal surface protein A (PspA) 
PspA is found in practically all clinical isolates of pneumococcus discovered to date 
(76). The majority of PspA molecules attach to the choline residues of lipoteichoic 
acids, which are anchored to the pneumococcal membrane (Fig. 3). A small fraction 
of PspAs might also be attached to the cholines of cell wall-associated teichoic acids 
(399). The PspA protein is remarkably variable at the sequence level. Based on 
sequence similarities, the proteins are divided to two major families, which can also 
be recognized serologically (152). PspA is required for full virulence in mouse 
models of pneumococcal disease (238), and it appears to be essential both for the 
ability of pneumococcus to colonize the nasopharynx and to cause lung infection 
and bacteremia (270). PspA binds the major iron transport protein lactoferrin, a 
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multifunctional protein that inhibits bacterial adherence and colonization on mucosal 
surfaces (130, 133). The binding of lactoferrin could aid the bacteria in the 
acquisition of iron on mucosal surfaces, or at the site of infection (130, 133). PspA 
has also been shown to bind apolactoferrin, the iron-depleted form of lactoferrin that 
has both bacteriostatic and bactericidal properties (330). The apolactoferrin that 
binds to PspA appears to be blocked from being able to kill pneumococci and even 
secreted forms of PspA could inhibit killing (330).  
 
2.3.4 Pneumococcal surface protein C (PspC) 
PspC is a multifunctional cell-surface protein known by several names, which reflect 
its different activities. The PspC family consists of 11 groups of polymorphic 
proteins with structural similarities, encoded by alleles of the same gene locus (164). 
Some of the alleles in the pspC locus encode choline binding proteins (Fig. 3) while 
some of the PspC proteins anchor directly to the cell wall (164). PspC has been 
shown to contribute to nasopharyngeal colonization and pneumonia (20, 271, 272), 
and it appears that PspC is important for translocation from the nasopharynx to the 
lungs and in crossing the blood-brain barrier (271). PspC has important roles in 
promoting adhesion to and translocation across epithelial layers (4, 132, 134, 292, 
310, 405). Allelic forms have been named after their functional and binding 
characteristics.  
 
Epithelial cells in the respiratory tract transport polymeric IgA from the basolateral 
surface to the lumen resulting in the presence of a polymeric immunoglobulin 
receptor (pIgR)/antibody complex on the apical surface (251). Cleavage of this 
complex permits the release of the antibody and a portion of the receptor that 
remains attached to the antibody (secretory component, SC). Unoccupied pIgR on 
the apical surface is recycled and returns to the basolateral surface for subsequent 
attachment to immunoglobulin. Apical recycling of the pIgR on the mucosal 
epithelium acts as an adherence mechanism for pneumococci. Some alleles of the 
PspC family can bind to pIgR, consequently enhancing transmigration of 
pneumococci from the apical to the basolateral face of the cells (51, 100, 405). PspC 
proteins choline binding protein A (CbpA) and secretory pneumococcal surface 
protein A (SpsA) bind the secretory immunoglobulin A (SIgA) via the secretory 
component (SC) (134, 344). Because excess of free SC and SIgA is present in the 
mucosal cavity, saturation of PspC by the binding of free SC or SIgA might 
decrease adherence mediated by the pIgR (99, 134). PspC has been shown to bind to 
host cells via secreted complement component C3 (310, 344). Clinical 
pneumococcal isolates, which are especially capable of binding to human lung 
epithelial cells, use PspC to bind to C3 on epithelial surfaces (305). Type II 
pneumocytes are known to synthesize and secrete complement component C3 (352), 
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providing a target for pneumococci to adhere to those cells via PspC. PspC also 
binds factor H (169, 170, 289). Factor H attached to the surface of pneumococci via 
PspC significantly enhanced pneumococcal adherence to host epithelial and 
endothelial cells (132). The integrin CR3 (CD11b/CD18) of human 
polymorphonuclear leukocytes was identified as the cellular receptor recognizing 
factor H (91). Pneumococcal entry into CR3-expressing epithelial cells via factor H 
is based on a two-step mechanism, where the initial contact of factor H-coated 
pneumococci is mediated by glycosaminoglycans expressed on the surface of human 
cells, and the pneumococcal uptake is mediated by integrins and depends on host 
signaling molecules (4). 
 
 
Figure 3. Pneumococcal surface structures. Diagrammatic representation of S. 
pneumoniae depicting several surface components for which roles in virulence have 
been described. PsaA, pneumococcal surface adhesin; PspA, pneumococcal surface 
protein A; PspC, pneumococcal surface protein C. F-antigen is a choline containing 
lipoteichoic acid bound to the bacterial cell membrane (50), whereas C-
polysaccharide is a teichoic acid linked to the cell wall. Originally published in (47) 
and reproduced with the permission of the copyright holder, Mary Ann Liebert Inc. 
Other important virulence factors not shown in the figure are pneumococcal pili and 
histidine triad proteins. Pili, expressed by many but not all pneumococci, are 
anchored to the cell wall. Electron microscopy images have indicated that pili 1 are 
shorter and cover most of the surface of the pneumococcus, while pilus 2 only exists 
as one or two copies, which extend further from the cell (19). Pneumococcal 
histidine triad proteins A, B, D and E have been detected on the bacterial surface by 
flow cytometry with antisera (2).  
THL 2011 – Research 58 35 
Interplay of Virulence Factors 
in Complement Resistance of 
Streptococcus pneumoniae 
 
2.3.5 Pneumolysin 
Pneumolysin is a major pneumococcal cytolysin that is produced by all known 
clinical isolates of S. pneumoniae regardless of serotype and genotype (173). It is a 
is a conserved thiol-activated, intracellular toxin (Fig. 3) that has multiple roles in 
the inflammatory reaction (150, 234). It contributes to the early pathogenesis of 
invasive pneumococcal pneumonia by facilitating intrapulmonary bacterial growth 
and invasion into the blood (317). The toxin is able to lyze eukaryotic cells; it 
disrupts the respiratory tract epithelium and inhibits cilial movement (41, 107, 316). 
Pneumolysin production is not a major determinant of successful nasopharyngeal 
colonization by pneumococci (318). 
 
2.3.6 Pneumococcal pili 
Some pneumococcal isolates express a pilus-like structure, which is able to extend 
beyond the polysaccharide capsule (23, 143). Pilus expression has been shown to 
mediate adherence to respiratory epithelium (19, 23). Pilus 1 is composed of three 
pilus subunits (RrgA, RrgB, and RrgC) (23, 143, 209). RrgA is considered to be the 
major pilus-associated adhesin, due to its localization at the tip of the pilus (257). 
The density of bacteria colonizing the upper respiratory tract of mice inoculated with 
piliated but RrgA-negative pneumococci was significantly less compared with the 
wild-type (257). The structural protein of pilus 2 is PitB, and adherence appears to 
rely solely on this pilus backbone protein (19). Pili 1 cover most of the surface of 
pneumococcus, while pili 2 are found in single copies and extend further from the 
cell (19). The pilus genes are not present in all the pneumococcal strains and clinical 
isolates: pilus 1 is present in less than 30% and pilus 2, only in less than 17% of the 
isolates (5, 19, 25, 249). 
 
2.3.7 The capsule 
The pneumococcal capsule is synthesized extensively during the exponential growth 
phase, and it is the thickest of the three surface layers of encapsulated pneumococci. 
With the exception of serotype 3, and possibly some other serotypes, the capsule is 
covalently attached to the outer surface of the cell-wall peptidoglycan (349). The 
capsular polysaccharide (PS) consists of repeating oligosaccharide units of two to 
eight monosaccharides. The majority of the PSs are simple linear heteropolymers, 
though some form more complex branched structures (7). The presence of the 
capsule can be verified by the Quellung reaction (15), in which bacterial cells are 
resuspended in antiserum that carries antibodies raised against the capsule. The test 
relies on the swelling of the capsule upon binding of homologous antibody, which 
can be visualized under a microscope.  
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Pneumococcus undergoes a reversible phase variation between opaque and 
transparent colony morphologies viewed in oblique light. Differences in colony 
opacity correlate with differences in virulence so that the transparent variants are 
more capable of colonizing the nasopharynx (190, 379, 382), whereas the opaque 
variants show increased virulence during systemic infections (190). Phase variation 
involves changes in the expression of surface molecules (190, 310). Most 
importantly, the opaque phenotype has more capsular polysaccharides compared 
with the transparent form (379). It has been demonstrated in vitro and in vivo that a 
phenotypic switch involving the down-regulation of the capsule exposes adhesion 
proteins in the nasopharynx for colonization, whereas up-regulation of capsule 
expression ensures abundant capsulation in systemic disease (135, 380). The capsule 
is one of the major virulence factors of S. pneumoniae. Loss of the capsule greatly 
attenuates virulence in animal models of disease (374). Pneumococcal strains that 
produce more capsule subunits in vitro are more virulent in vivo (226). All invasive 
clinical isolates are encapsulated, and the polysaccharide capsule is recognized to be 
the sine qua non virulence determinant for the bacterium.  
 
The degree of encapsulation has not been previously shown to strongly impact 
nasopharyngeal colonization (228), but in a more recent study the serotypes most 
prevalent in carriage were found to be more heavily encapsulated (378). A 
minimum amount of the capsular polysaccharide is absolutely required for efficient 
nasopharyngeal colonization in mice (228). Pneumococcal variants expressing 
larger amounts of negatively charged capsule subunits per cell were less likely to 
adhere to surfaces coated with human mucus and more likely to evade initial 
clearance in vivo (258). Unencapsulated pneumococcal mutants retained their 
capacity for nasal colonization in mice, but at a reduced density and duration 
compared to their encapsulated parent strains (258). This impaired colonization 
could be attributed to the fact that unencapsulated mutants remain agglutinated 
within luminal mucus and are, thus, less likely to reach the epithelial surface, where 
stable colonization occurs. Expression of the capsule may also be beneficial upon 
subsequent invasion to the lungs and bloodstream, because it could affect 
susceptibility to trapping by neutrophil extracellular traps (NETs) (372) and killing 
by defensins (26). In humans, unencapsulated pneumococci are relatively frequently 
isolated from superficial infections such as AOM (136), but isolates that lack the 
capsule rarely cause invasive disease (141). Although a thick capsule could allow 
the bacterium to persist in the nasopharynx, lungs, and blood by protecting against 
host immune effectors, a large capsule could hinder the invasion process itself 
(301). Bacteria attached to the epithelium tend to be less heavily encapsulated than 
unattached pneumococci (135). It has been suggested that direct interaction with 
epithelial cells can promote invasion into underlying tissue and blood, and a thick 
capsule could disrupt this process (77, 78).  
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2.3.8 Biofilm formation 
A biofilm is a highly structured, sessile microbial community characterized by 
bacterial cells attached to a surface or interface and embedded in a matrix of 
extracellular polymeric substances (74). Current evidence suggests that biofilm 
formation is a rather common feature among pneumococci that fits with some types 
of infections caused by this microorganism (AOM, meningitis), which have often 
been associated with the ability to form biofilm (65). In stable colonization 
pneumococci are likely to reside in the glycocalyx, which is the glue that holds the 
biofilm fast to the colonized surface (74, 258). The glycocalyx is a thin mucus-
containing layer overlying epithelial cells, which consists of a complex of 
exopolysaccharides of bacterial origin and trapped exogenous substances found in 
the local environment, including nucleic acids, proteins, minerals, nutrients and cell 
wall material (74). Biofilm provides a physical barrier that enhances pathogen 
resistance to host defenses such as opsonization, lysis by complement, and 
phagocytosis (75). Pneumococci induced to form a biofilm in vitro had a greater 
propensity to cause pneumonia or meningitis, while planktonic cells from liquid 
culture were more effective in inducing sepsis (266). In the biofilm, pneumococcus 
exists in its unencapsulated form; the presence of a capsule reduces biofilm 
development (250). The reduced capsule is important in initial airway colonization 
both for facilitating the initial adherence and for promoting cell-cell interactions for 
biofilm formation (179). Many pneumococcal surface proteins, for example LytA, 
PspA, and PspC, seem to be important in biofilm formation, as mutants not 
expressing them had a decreased capacity to form a biofilm (250). Proteins involved 
in adhesion and virulence were more abundant under biofilm growth conditions (6). 
The ability of pneumococci to regulate capsule expression could play a fundamental 
role in the transition from the carrier state to invasive disease (366). It may be that, 
in the carrier state, pneumococcus constitutively adopts the sessile mode of growth 
in order to survive for long periods of time. 
 
2.4 Virulence factors involved in complement inhibition in 
invasive disease 
2.4.1 Complement evasion mechanisms of pathogenic bacteria 
Immune-evasion strategies of pathogenic microorganisms are often focused on the 
complement system, which is the centerpiece of innate immunity and generally 
regarded as the first line of defense. Many, if not all, human pathogens have found 
ways to escape complement attack through a range of different mechanisms (201). In 
order to inhibit classical and lectin pathways, many microbes have developed the 
ability to bind to C4BP, which is a key inhibitor of these pathways, whereas 
protection from the alternative pathway is provided due to the capturing of factor H, 
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the major inhibitor of this pathway (34, 170). Another bacterial complement evasion 
strategy is to capture and inactivate the central molecule of all pathways of 
complement, C3. Furthermore, proteases with specificity for complement factors can 
efficiently destroy the bactericidal activity of serum.  
 
The importance of complement in host defense against pneumococci is substantiated 
by the fact that the bacterium processes a variety of complement-evasion 
mechanisms. These activities involve interference with complement activation, 
inhibition of the deposition of opsonic C3 fragments, and perturbation of ligand-
receptor interactions involved in opsonophagocytosis (333). The rigid gram-positive 
cell wall of S. pneumoniae prevents the bacteria from being lyzed by the membrane 
attack complex. The capsule prevents opsonophagocytosis by impairing CRP and 
antibody binding to the bacterial surface. It also reduces classical pathway 
activation, although the mechanism for this is not clear. The capsule is not the only 
strategy the pneumococcus uses to avoid complement and phagocytosis. Several 
pneumococcal proteins have been suggested to interfere with complement 
deposition, including PspA, PspC, and pneumolysin (172) and, more recently, 
pneumococcal histidine triad (Pht) proteins (269). In the following sections, the 
virulence factors that are considered to contribute to complement resistance of 
pneumococci are sidcussed in more detail. 
 
2.4.2 PspA 
PspA appears to protect S. pneumoniae from the host complement system and 
subsequent phagocytosis by macrophages (397, 399). Mutant strains of 
pneumococci not expressing PspA were cleared more rapidly from the blood of 
nonimmunized mice than the wild-type strain (49), whereas PspA pneumococci 
that were avirulent in normal mice were fully virulent in C3-deficient and factor B-
deficient mice (365). Compared to wild-type pneumococcus, more C3b and iC3b 
were deposited onto the PspA strain, and the PspA strain also consumed more 
circulating host C3 than the wild-type strain (296-298, 365). Serum from a wild-
type mouse supported more deposition of C3 onto the pneumococcal surface than 
serum from factor D- or factor B-deficient mice, and this decrease in the deposition 
of C3 in vitro correlated with impaired host resistance to infection (296, 297). PspA 
is suggested to inhibit the classical pathway (297) by interfering with the C1q 
initiation step, since the absence of PspA allows greater deposition of C1q and, thus, 
increased classical pathway-mediated C3 deposition (213). The anti-complement 
effect of PspA could be overcome by antibodies to PspA, allowing increased 
complement activation and C3 deposition on the bacteria (265, 297). Despite the 
wide diversity of PspAs, members from two PspA families had the same inhibitory 
effect on the activation and deposition of human C3 and on virulence in mice, when 
THL 2011 – Research 58 39 
Interplay of Virulence Factors 
in Complement Resistance of 
Streptococcus pneumoniae 
 
the role of the PspA family was examined in isogenic strains with the same 
genotype (298).  
 
2.4.3 PspC 
As a complement evasion strategy, some pathogenic microorganisms recruit fluid-
phase-soluble complement regulators to their surface. Factor H is a central host 
protein that is acquired by pathogens and attached to the pathogen surface to avoid 
complement-mediated killing. Most members of the PspC family can bind factor H, 
but the efficiency of factor H binding varies among pneumococcal strains (291). 
Factor H binding accelerates the degradation of C3b on the bacterial surface and 
inhibits the formation of new C3 convertases, which decreases the net C3b 
deposition (169, 170). Pneumococcus has also been shown to bind the complement 
inhibitor C4b-binding protein (C4BP) (89). C4BP is the major soluble inhibitor of 
the classical and lectin pathways. It inhibits the formation and accelerates the decay 
of the classical pathway C3 convertase (C4b2a) (83, 408). The binding of C4BP, 
like the binding of factor H, is dependent on PspC. However, C4BP binding seems 
to be restricted to certain serotypes, of which the strains of serotype 14 are the 
strongest binders and most of the high-binder strains harbor a specific allele of PspC 
(89, 404). The failure of S. pneumoniae to inhibit classical pathway activity by 
binding C4BP may be one possible explanation for the importance of the classical 
pathway in immunity to pneumococci. 
 
The contribution of PspC to the virulence of pneumococci appears to depend on the 
strain. The deletion of PspC in the serotype 2, 3, and 19F strains did not significantly 
alter their virulence in a murine model of pneumococcal disease, whereas the 
virulence of a serotype 4 strain was reduced in both pneumonia and bacteremia 
models (183). Allelic variation in PspC structure may affect its interaction with the 
complement system. Comparison of several pneumococcal strains with different 
genetic backgrounds (genotypes) indicated that the effects of loss of PspC on C3 
deposition are largely dependent on the genotype (403). 
 
PspA and PspC may complement each other in their abilities to block the clearance 
of pneumococci by interfering with complement activation. Deleting PspA from a 
wild-type strain reduced virulence only moderately, but deletion of PspA from a 
strain lacking PspC caused a 10,000-fold decrease in virulence (47, 52). The 
deletion of PspC alone seemed to have little (290) or practically no effect (213) on 
complement deposition, while deletion of both PspA and PspC resulted in higher 
C3b deposition than when only one of the proteins was missing (213, 290). The 
results indicate that PspA and PspC markedly reduce complement deposition by 
inhibiting both the classical and alternative pathways. The absence of PspA and 
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PspC resulted in greatly increased immune adherence to human erythrocytes and 
improved the transfer of pneumococci from erythrocytes to phagocytes, which was 
suggested to be the mechanism for how PspA and PspC act in synergy to protect 
pneumococci from complement-dependent clearance during invasive infection 
(213). 
 
2.4.4 Pneumolysin 
The principal activities of pneumolysin have been viewed as the capacity to induce 
pores in cholesterol-rich membranes and the ability to activate complement, both of 
which play a role in virulence in an animal model of pneumonia (315). Pneumolysin 
contributes to complement resistance by quenching complement away from the 
pneumococcal surface (279) by activating the classical pathway of complement in 
the absence of antibodies (159, 279). Deletion of the gene encoding pneumolysin 
results in increased opsonophagocytosis of pneumococci via the classical pathway, 
which suggests that complement activation by the released toxin, pneumolysin, 
occurs at a distance from the organism and the original infection site, leaving less 
complement available to deposit on the bacterial surface (401). Comparison of 
single and double mutants showed that the two proteins work in concert; lack of 
both PspA and pneumolysin resulted in higher C3 deposition than either single 
mutation (401).  
 
2.4.5 Pneumococcal histidine triad (Pht) proteins 
Pht proteins were originally identified by immunoscreening from the genomic 
library of S. pneumoniae in search for surface-localized, immunogenic, and 
protective vaccine antigens (389). Pht proteins form a group of pneumococcal 
surface proteins characterized by a histidine triad motif, repeated five to six times in 
their amino-acid sequence (2). Four members of this family, with high sequence 
conservation between them, have been described: PhtA, PhtB, PhtD, and PhtE (131). 
PhtB and PhtD are most similar with 87% sequence homology, whereas PhtE shares 
only 32% similarity with the other Pht proteins (2). PhtA, PhtB, and PhtD have five 
histidine triads in their amino acid sequence; PhtE has six (2, 389). Results from 
antibody labeling and flow-cytometric experiments demonstrated that the Pht 
proteins are exposed on the surface of the encapsulated bacterium (131). The Pht 
proteins are well-conserved across the pneumococcal species (131, 406). The phtD 
gene was found to be present among all pneumococcal strains tested, and genes for 
PhtE, PhtB, and PhtA were found in 97%, 81%, and 62% of the strains, respectively 
(302). Fifty-four percent of the strains were found to carry all four pht genes in their 
genome (302). The pht genes are located in tandem pairs in the chromosome (2), but 
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their expression is controlled individually; phtA, phtB, and phtE each possess their 
own promoter, whereas phtD is under the control of an lmb-phtD operon (269, 274).  
 
Deletion of one or two of the Pht proteins did not result in significant attenuation of 
the pneumococcal strain D39 in systemic disease compared with the wild-type 
pneumococcus, whereas the mutant lacking all four Pht proteins was completely 
avirulent (269). The observed functional redundancy is perhaps not surprising given 
the notable conservation of amino acid sequence between Pht proteins (2). In the 
pneumonia mouse model, the phtA-phtB deletion mutant, as well as the mutant 
lacking all Pht proteins, was significantly attenuated compared with the wild-type 
D39 (269). In contrast, single mutants lacking PhtA, PhtB, or PhtD in the TIGR4 
strain were highly attenuated in the lung infection of mice (143). Several 
mechanisms of how Pht proteins may contribute to the virulence of pneumococcus 
have been suggested, and it is possible that they have pleiotropic functions. The high 
number of histidine residues in the histidine triads could imply that the Pht proteins 
play a role in DNA and/or metal binding (2) and could be involved in the adhesion 
and invasion process on mucosal surfaces where zinc concentration is low (274). 
The crystal structure of PhtA was reported to contain a zinc-binding motif (299), and 
the gene coding for PhtD is upregulated in zinc depletion as a member of an lmb-
phtD operon (274). In another streptococcal species, S. agalactiae, the Lmb protein 
was shown to mediate bacterial attachment to human laminin, which is essential in 
bacterial colonization of damaged epithelium and translocation of bacteria into the 
bloodstream (350). A recent study suggests that Phts are regulators of metal 
homeostasis, Zn2+ and Mn2+ scavengers, with the function of storing and 
concentrating these divalent cations (302). As such, they may play a role in ion 
storage, particularly zinc, in order to make it available when the bacterium faces ion-
restricted environments, as is the case during the early stages of infection (60, 140).  
 
A role in immune evasion has also been postulated through suggestions that a 
fragment of PhtB (also termed PhpA) could cleave human complement component 
C3 (9, 155). It was suggested that PhtB would degrade soluble C3 proteolytically 
before deposition on the bacterial surface. This activity, however, has not been 
demonstrated directly. A more recent study suggests that Pht proteins would inhibit 
complement activation by binding factor H in a manner similar to PspC  (269). 
Deletion of all four Pht proteins was reported to significantly increase C3 deposition 
on the bacterium, and the Pht proteins were reported to bind factor H (269). As in 
the mouse model of invasive pneumococcal disease, deletion of a single Pht protein 
had no effect on C3 deposition, suggesting overlapping roles for the Pht proteins in 
complement evasion (269). 
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2.4.6 The capsule 
The pneumococcal capsule protects against phagocytic clearance by blocking the 
binding of antibodies directed against cell-surface antigens and deposition of opsonins 
(C3b and iC3b) on cell wall structures. The majority of C3b molecules are deposited 
on the cell wall, whereas capsule-bound C3b constitutes a minority of C3b molecules 
bound on encapsulated pneumococci (156). The capsule forms an inert shield that 
prevents the Fc region of IgG or opsonins bound to deeper cell-surface structures (for 
example, teichoic acids and cell-surface proteins) from interacting with their relevant 
receptors on phagocytic cells, thus impeding phagocytosis by Fcγ receptors and 
complement receptors. By reducing the binding of IgG and CRP on the bacteria, the 
capsule also inhibits activation of the classical pathway (162). The capsule may also 
inhibit bacterial interactions with nonopsonic phagocytic receptors such as mannose 
or scavenger receptors (12, 13). Although the neutrophil-mediated killing of 
pneumococci occurs in the absence of opsonins (378), neutrophil phagocytosis is 
markedly increased by opsonization of pneumococcus with complement (404). 
Complement deposition on isogenic S. pneumoniae TIGR4 mutants expressing 
different serotypes is correlated with neutrophil phagocytosis in the presence of 
complement, but differences in phagocytosis between strains were abolished when the 
bacteria were not opsonized with complement (163).  
 
Reduced expression of the capsule results in greater access of antibodies and 
complement to the pneumococcal surface (228) and, hence, increased clearance by 
the immune system. However, the serotype of the capsule appears to be more 
important than its thickness to the ability of the capsule to inhibit complement 
deposition (163). Swap of the capsule type affected the accessibility of surface-
bound complement and surface antigens of S. pneumoniae (1). Hostetter suggested 
that the antiphagocytic nature of the capsule might reside in its capacity to both 
permit C3b deposition and to enhance the proteolytic degradation of capsule-bound 
C3b to fragments that are recognized by phagocytes (iC3b) or fail to serve as 
ligands for phagocytic receptors (C3d) (155, 156). The absolute number of C3b 
bound on pneumococcal strains, in the study by Hostetter et al., did not correlate 
with the ranking order of how resistant serotypes are to opsonophagocytosis (155, 
156). More recently, it has been reported that factor H bound to PspC is able to 
promote cleavage of C3b to iC3b (and C3d) by factor I, and that the effect of PspC 
on C3b/iC3b deposition depends on strain background and is largely independent of 
capsular serotype (402), implying that it is more likely that Hostetter’s observations 
of C3b degradation were dependent on other factors than the capsular serotype.  
 
Pneumococcal serotypes differ markedly in their capacity to cause disease (17). It 
has long been observed that certain serotypes, particularly 1 and 2, appear to be 
more “invasive” than other serotypes because they are not commonly carried by 
THL 2011 – Research 58 43 
Interplay of Virulence Factors 
in Complement Resistance of 
Streptococcus pneumoniae 
 
healthy individuals (343, 351). An inverse correlation has been found between 
carriage prevalence and the invasiveness of pneumococcal serotypes (56). In order 
to compare the disease potential of different capsular types, the prevalence of 
serotypes among isolates from disease has been related to their prevalence in 
carriage (54, 136). Clones from certain serotypes were found to be significantly 
associated with invasive disease, while others appear to have a low disease-causing 
potential (54). Some serotypes, such as 1, 4, 5, 7F, and 14, are overrepresented 
among invasive isolates (54, 56, 137, 200, 320, 332, 342). Hanage et al. (2004) did 
not find significant differences among clones and serotypes in the risk of 
progression from carriage to AOM (136). In contrast, Shouval et el. (2006) reported 
a significant association of serotypes 1, 3, 5, 12F, 19A, and 19F with AOM (332). 
The differences in measures of serotype-specific potential to cause invasive or 
mucosal infections may be due to differences in disease potential between clones 
within the same serotype. The strong association of certain serotypes with invasive 
disease implies that the capsule type may be important in invasive disease, but in 
mucosal infections it may play a lesser role. A comparison of pneumococcal strains 
isolated from carriage and invasive disease suggests that carriage isolates are more 
heterogeneous, whereas clonal characteristics are likely to be advantageous for 
invasiveness (54, 304).  
 
In addition to the capsular type, the combination of the capsule and the genotype of 
the pneumococcal strain was shown to be important and vary with the site of 
infection when capsule-switched mutant strains were studied in respiratory tract 
infections of mice (178). Although isogenic pneumococci expressing different 
capsule serotypes exhibit marked differences in murine virulence, non-capsular 
factors are also clearly important (182). In multi locus sequence typing (MLST) the 
allelic profile of a pneumococcal strain is obtained by sequencing internal fragments 
of seven house-keeping genes clones (101). Strains of different multi-locus sequence 
types expressing the same capsular serotype may have different virulence properties 
(326). Disease kinetics in mouse models varied significantly between clonal types 
within serotypes 1, 4, 6B, 7F, 14, and 19F (326). Differences in invasive disease 
potential between clones sharing the same serotype were also found among 
serotypes infecting humans. The propensity of clones to cause invasive disease in 
humans varied significantly among serotypes 3, 6A, 6B, 14, 19A, 19F, and 23F 
(320). Molecular epidemiological analysis has demonstrated that properties 
associated with a particular clonal type, in addition to capsular serotype, influence 
the potential of S. pneumoniae to cause invasive disease in humans. Certain clones 
have been particularly successful and have acquired multiple serotypes (55, 216). 
This supports the notion that other genetic factors influence the fitness of a 
pneumococcal strain. The relative contribution of the capsular type compared to 
other virulence factors in different pneumococcal diseases is still unclear. Since 
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considerable genetic diversity exists between strains, it is difficult to assess the 
significance of capsule versus other virulence factors. Recent studies using capsule-
switched mutants show that protection against complement-mediated immunity 
varies between capsular serotypes even when expressed in an otherwise isogenic 
background (163). 
 
2.5 Prevention of pneumococcal disease  
2.5.1 Polysaccharide vaccines 
Pneumococcal polysaccharide vaccines contain purified capsular polysaccharides 
from the serotypes most prevalent in industrialized countries. The first such vaccine 
included 14 serotypes and was licensed in 1977, and in the early 1980s the valence 
was increased to 23 serotypes. The vaccine serotypes represent 85 to 90% of the 
serotypes that cause invasive infections in the USA (Table 3).  
 
The polysaccharides induce production of antibodies by stimulating clonal 
expansion of B cells by binding and cross-linking the B-cell receptor. Since 
polysaccharides are unable to recruit CD4+ T cell help through T-cell receptor 
recognition of peptide-major histocompatibility complex II, the antibody titers do 
not rise beyond the primary level after multiple exposures (139).  The immaturity of 
B cells in young children makes them unresponsive to polysaccharide antigens, 
rendering such vaccines useless in children under 2 years of age (110). The PS-
vaccine is effective in the prevention of bacteremia in adults. However, it does not 
offer protection against pneumonia, which is a more common manifestation of 
pneumococcal infection in elderly persons (153, 165, 331). 
 
2.5.2 Conjugate vaccines 
In the pneumococcal conjugate vaccines, capsule oligosaccharides are covalently 
conjugated to carrier proteins; e.g. a non-toxic mutant diphtheria toxin or protein D 
of Haemophilus influenzae (286). Conjugation of the polysaccharide to a protein 
carrier overcomes the problem of poor immunogenicity of the plain polysaccharide. 
The peptide part of the vaccine is recognized by T-cell receptors, which leads to a 
T-cell-dependent response: long-lived memory B cells, booster effect, and affinity 
maturation of the antibody response. Most importantly, the responses will take place 
in young children (110). The first 7-valent, pneumococcal conjugate vaccine was 
licensed in 2000 in the USA and in 2001 in Europe. The formulations of 
pneumococcal conjugate vaccines are listed in Table 3. 
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Table 3. Formulations of pneumococcal vaccines  
Valence Serotypes Protein carrier References 
Polysaccharide  
23* 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 
10A, 11A, 12F, 14, 15B, 17F, 
18C, 19F, 19A, 22F, 23F, 33F 
 (303) 
Polysaccharide conjugated to protein carrier (PCV) 
7* 4, 6B, 9V, 14, 18C, 19F, 23F CRM-197 (33, 103, 262, 
387) 
7 4, 6B, 9V, 14, 18C, 19F, 23F OMPC (187) 
9 PCV7 + 1, 5 CRM-197 (79, 194, 236) 
10* PCV7 + 1, 5, 7F PD, DT and TT (383) 
11 PCV7 + 1, 3, 5, 7F PD (286) 
11 PCV7 + 1, 3, 5, 7F DT and TT (81, 223) 
13* PCV7 + 1, 3, 5, 6A, 7F, 19A CRM-197 (59, 185) 
The list is not exhaustive and includes licensed* vaccines and examples of vaccine 
formulations used in clinical trials. CRM-197, derivative of diphtheria toxin; DT, 
diphtheria toxoid; PD, H. influenzae outer membrane protein D; OMPC, 
meningococcal outer membrane protein complex; TT, tetanus toxoid. 
 
 
The pneumococcal conjugate vaccine is efficacious in preventing serious forms of 
pneumococcal disease caused by the serotypes included in the vaccine (33, 79, 194, 
262, 385). However, a case-control study in the USA suggests less efficient 
protection against invasive disease caused by serotype 19F (387). In The Gambia, 
the efficacy of the 9-valent vaccine was significant against invasive disease caused 
by serotypes 5, 14, and 23F, whereas despite good immunogenicity, the vaccine 
appeared to lack protective efficacy against serotype 1 (79, 321). The antibody 
concentration required for protection from colonization and mucosal infections is 
likely to be higher than for systemic disease (38). Marked variation was observed 
among pneumococcal serotypes in the efficacy of conjugate vaccines against AOM 
(103, 187, 286). The efficacy against pneumococcal AOM was good against 6B and 
23F, but poor against 19F (103, 187), although the antibody concentrations after 
vaccination were the lowest for 6B and 23F and highest for 19F (97, 187). Lower 
efficacies against AOM caused by 19F have been reported in other studies as well 
(33, 261, 286).  
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2.5.3 Serotype replacement 
In the first clinical trials of a tetravalent polysaccharide vaccine, it was found that if 
an individual was a carrier of a pneumococcal serotype represented in the vaccine, 
vaccination would not eliminate the carrier state, but if the individual was not a 
carrier, vaccination would reduce by half the likelihood of becoming one (227). The 
pneumococcal conjugate vaccines have since been shown to reduce acquisition of 
vaccine-type pneumococcal carriage, thus inducing indirect protection against 
carriage and disease in the unvaccinated, but also potential for replacement of 
nonvaccine types as causes of carriage and disease (103, 148, 161, 212). Although 
several studies have reported that pneumococcal conjugate vaccines decrease 
nasopharyngeal carriage of serotypes included in the vaccine (80, 82, 236, 264), the 
overall carriage rate has not diminished. This is because the ecological niche has 
been replaced by serotypes not immunologically related to the vaccine serotypes. In 
the USA, vaccine-type carriage has been replaced by non-vaccine-type carriage 
during the large-scale use of the vaccine since 2000 (77, 147, 161, 247, 281). Due to 
the ability of pneumococci to naturally take up DNA, they might readily escape 
selection pressure from vaccines directed at only a few serotypes by means of 
capsular switching. Well-known serotype switches include 23F to 19F, 23F to 14, 
23F to 19B, 19A to 11, 14 to 19A, 14 to 9V, and 14 to 9A (87). Virulent, multi-
drug-resistant pneumococcal clones circulating around the world seem to have the 
ability to change capsular type in vivo without loss of virulence (259).  
 
2.5.4 Protein vaccines 
While more than 20 pneumococcal serotypes may cause invasive disease, only a 
limited number of the capsule antigens can in practice be conjugated to a carrier 
protein. The use of pneumococcal protein antigens able to afford protection across 
the majority of serotypes is envisaged as a relevant alternative and/or addition to the 
use of polysaccharides in vaccines. Several proteins have been studied as potential 
future vaccine candidates. Virulence proteins are attractive targets, as they are 
essential to the bacteria and loss-of-function mutants are avirulent or show 
decreased virulence. Antibodies to surface-located proteins have the ability to both 
neutralize the virulence function and enhance phagocytosis by opsonizing bacterial 
surfaces. Pneumococcal surface proteins may provide cross-immunity regardless of 
serotype and have been investigated as carriers of polysaccharide antigens or used 
per se as potential vaccines. Proteins are immunogenic even in young children, and 
pure protein antigens would be less expensive since the costly conjugation process 
is unnecessary (44). 
 
Antibodies directed against pneumococcal pilus structures were protective in mouse 
models of invasive disease against a pilus-expressing pneumococcal strain (115). 
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However, because pneumococcal pili are present in only a fraction of clinical 
isolates (19), they should be used in combination with other protective antigens to 
obtain broad-coverage, protein-based vaccines. Pneumococcal virulence proteins 
PspA, pneumolysin (278), PsaA (248), and Phts (2) are produced by virtually all 
clinically important pneumococcal strains, and proteins of the PspC family are also 
collectively expressed by most strains (164). Unlike pspA and pspC gene loci, the 
genes of PsaA (167) and pneumolysin (48) are relatively invariant. Phts are also 
highly conserved (2). The ability of a vaccine to prevent nasopharyngeal carriage is 
an important property, given that a reduction in carriage is likely to reduce 
transmission of pneumococci and acquisition of pneumococcal infection (278). 
Intranasal immunization of mice with PsaA was observed to reduce the bacterial 
load in nasopharyngeal carriage (43, 86). Also, protection against carriage increased 
to a greater degree in combination with PspA than after immunization with PsaA 
alone (43). Immunization with PspC has been effective in protection against 
nasopharyngeal carriage in mice (44). Immunization with PspA virtually eliminated 
nasal carriage (392). It has provided evidence of protection against otitis media in 
animal models (45, 384). PspA is also strongly protective against invasive disease 
(44), whereas immunization with PsaA failed to protect mice against systemic 
infection despite the protective effects against carriage (267). Immunization of mice 
with a PhtB antigen reduced nasopharyngeal colonization (406), and PhtB and PhtE 
antigens conferred protection against sepsis and pneumonia (131). In a 
nasopharyngeal colonization model and in a lung colonization model, Phts were 
found to be superior to PspA, PsaA, and PspC in terms of efficacy of protection and 
serotype coverage (119). Moreover, even natural anti-PhtD human antibodies 
transferred into mice in a passive transfer model demonstrated significant protection 
against lethal intranasal challenge (119). Previous studies in animal models suggest 
that immunization with a mixture of proteins provides the best protection from 
pneumococcal carriage or disease (43, 46, 267). The protective efficacy of the 
immunization of mice with pneumolysin, PspA, PspC, PhtB, and PhtE was assessed 
in an invasive-disease model (268), and a synergistic or additive effect was seen by 
using multiple proteins even where the individual proteins showed little value by 
themselves.  
 
2.5.5 Resistance to antimicrobials  
Pneumococcal infections were successfully treated with antibiotics until the 
emergence of the first penicillin-resistant strains of S. pneumoniae in the 1960s. 
Since then, the proportion of strains resistant to penicillin and a wide range of other 
antibacterial agents used in the therapy of pneumococcal infections has steadily 
increased (214). Multi-drug-resistant strains are becoming more common, some 
being susceptible only to vancomycin (386). The incidence of antibiotic resistance 
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varies geographically, most likely due to differing policies of antibiotic usage (166). 
Aggressive antibiotic treatment of AOM and viral infections of the upper respiratory 
tract is believed to be the major factor in the rise of antimicrobial resistance (116). 
The majority of pneumococcal strains causing AOM are not susceptible to penicillin 
in many countries (142). The highest rates of resistance to penicillin and 
erythromycin worldwide were found in serotypes included in the 7-valent 
pneumococcal conjugate vaccine. A significant decline in the rates of antibiotic 
resistance in the USA has been seen since the introduction of the vaccine (214). It 
has been feared that resistance to antimicrobial agents might spread to or develop in 
nonvaccine serotype strains. The high prevalence of penicillin-nonsusceptible strains 
in the non-vaccine serotypes, even before the introduction of pneumococcal 
vaccines, suggested that these clones could be potential candidates for replacement 
disease (284). Indeed, the incidence of infections caused by non-vaccine serotypes, 
especially by multi-resistant serotype 19A pneumococci, has increased (295). 
Inclusion of this serotype in the 13-valent conjugate vaccine is likely to significantly 
reduce the burden of disease due to serotype 19A.  
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3 AIMS OF THE STUDY 
The capsular serotype, known virulence proteins, and the genotype, which is the 
unique combination of genes possessed by the pneumococcal strain, may all 
influence the ability of pneumococcus to resist complement and antibody-mediated 
protection and the resultant potential to cause disease. The general aim of the present 
study was to analyze the relative roles of the pneumococcal capsule and virulence 
proteins in evading complement attack and the subsequent opsonophagocytic killing. 
The importance of particular virulence factors to the complement resistance of a 
strain may vary depending on the genetic background. Prior studies have evaluated 
the effect of the capsule on complement resistance of pneumococci by comparing 
only very few strains (156, 163). Virulence proteins reported to influence 
complement inhibition have been assessed in only one or two strains (213, 269, 296-
298, 365). In this thesis, I have aimed to assess the role of pneumococcal virulence 
factors in complement resistance of the bacterium by comparing their effects in 
several different genotypes. 
 
The specific aims were: 
1. to assess the effect of pneumococcal histidine triad (Pht) proteins on 
complement resistance by comparing wild-type and knock-out mutants of 
several genotypes 
 
2. to study the ability of different pneumococcal serotypes to resist 
complement deposition and opsonophagocytosis by comparing clinical 
pneumococcal isolates that differ in their invasive disease potential 
 
3. to compare isogenic mutants as well as clinical isolates sharing the same 
MLST, which express different capsular serotypes, to distinguish the 
relative roles of the serotype and genotype in resistance to complement and 
opsonophagocytosis 
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4 MATERIALS AND METHODS 
The laboratory methods used in the studies of this thesis are listed in Table 4 and are 
described in more detail in the respective studies. An outline of the principal 
materials and methods is presented below. 
 
Table 4. Laboratory methods used in studies I-IV 
Method 
 
Used in  
Genetic methods  
Cloning of quadruple pht mutants I 
Cloning of capsule-switch mutants IV 
Multilocus sequence typing of pneumococcal isolates II 
Immunological methods  
Western blot analysis of expression of Pht proteins  I 
Overlay assay for analysis of factor H binding to bacterial cell lysates I 
Enzyme immunoassay for PspA family typing II 
Enzyme immunoassay for binding of factor H to pneumococcal proteins I 
Opsonophagocytic killing assay II-III 
Flow-cytometric methods  
Surface expression of pneumococcal proteins  I 
Complement C3 deposition on pneumococci  I-IV 
Factor H binding to pneumococci I, II 
 
 
4.1 Bacterial strains  
 
Clinical isolates of S. pneumoniae representing different capsular serotypes and 
genotypes as well as capsule-switched mutants and mutants lacking one or more 
surface proteins affecting the virulence of the bacterium were analyzed in this thesis. 
 
Knock-out mutants lacking all Pht proteins were made in five different genetic 
backgrounds (Table 5). Previously prepared PspA¯ and PspC¯ mutants in the D39 
background were analyzed along the Pht¯ mutant D39 to assess the relative impact 
of the different proteins.  
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Table 5. Pneumococcal strains of study I 
Strain  Serotype Description Reference/  
source 
D39  2 wild-type  (18) 
 
D39 Pht¯ 2 D39 derivative with phtA, phtB, 
phtD, and phtE deletions 
study I 
D39 PspA¯ 2 JY182, D39 derivative with pspA 
deletion 
(398) 
D39 PspC¯ 2 TRE108, D39 derivative with pspC 
deletion 
(130) 
D39 PspA¯PspC¯ 2 TRE121, D39 derivative with pspA 
and pspC deletions 
(130) 
R36A  Rough wild-type (ATCCa 27336), 
unencapsulated derivative of D39  
(18, 202) 
R36A Pht¯ Rough R36A derivative with phtA, phtB, 
phtD and phtE deletions 
study I 
43  3 clinical isolate, naturally lacks phtA clinical isolate, 
study I 
43 Pht¯ 3 43 derivative with phtB, phtD and 
phtE deletions 
study I 
4-CDC  
 
4 wild-type (DS2382-94) (308) 
4-CDC Pht¯ 4 4-CDC derivative with phtA, phtB, 
phtD and phtE deletions 
study I 
2737 19F clinical isolate, naturally lacks phtA clinical isolate, 
study I 
2737 Pht¯ 19F 2737 derivative with phtB, phtD 
and phtE deletions 
study I 
aATCC, American type culture collection 
 
Clinical isolates of selected serotypes were compared to explore potential 
differences between serotypes as well as variance within the serotypes in resistance 
to complement and opsonophagocytic killing (Table 6). The pneumococcal isolates 
of study II were characterized by multi-locus sequence typing (MLST), as described 
previously (101, 348). Isolates for study III representing different MLSTs were 
selected based on previously published data (136, 137). The mucosal isolates 
(nasopharyngeal carriage strains and middle-ear isolates from AOM) were collected 
for the FinOM Cohort Study from children under 2 years of age (188, 353). The 
invasive isolates came from blood cultures of Finnish children from the national 
infectious disease register (National Reference Laboratory for Pneumococcus, 
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National Public Health Institute, Oulu, Finland). Serotypes 1 and 5 are uncommon in 
Finland. The isolates of these two serotypes were selected from pneumococci 
isolated during clinical trials in The Gambia (3, 79). The clinical isolates were 
analyzed in parallel with the reference strains used in the opsonophagocytic assay. 
The reference strains of the single opsonophagocytic killing assay (OPA strains) 
(308) as well as of the multiplex OPA (MOPA strains) (39, 63) came from the 
Centers for Disease Control and Prevention, Atlanta. Capsule-switched mutants, 
which were constructed in three different genetic backgrounds, were compared with 
each other and with the donors of the capsule genes (Table 7). The invasive strains 
sharing the same MLST, but representing different serotypes, were isolated from 
Finnish children. They were obtained from the national infectious disease register.  
 
Table 6. Pneumococcal isolates of studies II and III 
Strain Serotype MLST Sample type Source Study 
MOPA1 1 NDa invasive SPEC-1 (L82006)  III 
INV1-1 1 618 invasive PVT0002 III 
INV1-2 1 1331 invasive PNI 0062 III 
INV1-3 1 3579 invasive PNI 0213 III 
INV1-4 1 3574 invasive PNI 0150 III 
CAR1-1 1 910 mucosal CH0089 III 
CAR1-2 1 2084 mucosal CH0053 III 
CAR1-3 1 3570 mucosal PVT 13506         III 
MOPA4 4 ND invasive OREP-4 (DS2382)  III 
INV4-1 4 176 invasive IO11147 III 
INV4-2 4 205 invasive IO11512 III 
INV4-3 4 205 invasive IO12680 III 
MOPA5 5 ND invasive STREP-5 (DBL5) III 
INV5-1 5 289 invasive PVT0020 III 
INV5-2 5 3313 invasive PVT0027 III 
INV5-3 5 3338 invasive PVT0018 III 
INV5-4 5 3339 invasive PVT0026 III 
Table 6 continues 
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Table 6 continues 
Strain Serotype MLST Sample type Source Study 
MOPA6B 6B ND invasive SPEC-6B (BG25-9)  III 
6B OPA 6B 176 invasive DS2212-94  II 
6B NP 6B 506 mucosal IOKOR 306-9 II 
6B MEF1 6B 147 mucosal IOKOR 1424-8 II 
6B MEF2 6B 506 mucosal IOKOR 248-7 II 
6B MEF3 6B 497 mucosal IOKOR 556-4 II 
6B INV1 6B 138 invasive io14922 II 
6B INV2 6B 1518 invasive io14924 II 
6B INV3 6B 138 invasive io14898 II 
MOPA14 14 ND invasive STREP-14 (DS2214-94) III 
INV14-1 14 124 invasive IO10163 III 
INV14-2 14 700 invasive IO626 III 
INV14-3 14 9 invasive IO12202 III 
MEF14-1 14 134 mucosal IOKOR1832-5 III 
MEF14-2 14 156 mucosal IOKOR2104-3 III 
MEF14-3 14 307 mucosal IOKOR392-1  III 
MOPA18C 18C ND invasive OREP-18C (GP116)  III 
INV18C-1 18C 496 invasive IO10148 III 
INV18C-2 18C 1016 invasive IO10162 III 
INV18C-3 18C 1073 invasive IO632 III 
MOPA19F 19F ND invasive SPEC-19F (DS2217-94)  III 
19F OPA 19F 688 invasive DS2217-94 II 
19F NP 19F 309 mucosal IOKOR 235-7 II 
19F MEF1 19F 534 mucosal IOKOR 1491-4 II 
19F MEF2 19F 3760 mucosal io16716 II 
19F MEF3 19F 236 mucosal io16650 II 
19F INV1 19F 1081 invasive io12089 II 
19F INV2 19F 43 invasive io12527 II 
19F INV3 19F 43 invasive io12690 II 
MOPA23F 23F ND mucosal EMC-23F (1212458)  III 
INV23F-1 23F 37 invasive IO11697 III 
INV23F-2 23F 36 invasive IO10783 III 
INV23F-3 23F 440 invasive IO10961 III 
MEF23F-1 23F 37 mucosal IOKOR46-1 III 
MEF23F-2 23F 515 mucosal IOKOR1101-8 III 
MEF23F-3 23F 535 mucosal IOKOR1617-3 III 
aND, no data 
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Table 7. Pneumococcal strains of study IV 
Strain Serotype  Capsule genes from/to Source/ reference 
Isogenic capsule-switched mutants 
TIGR4-R rough  Janus cassette (360) 
TIGR4-1 1  GA07694 (378) 
TIGR4-2 2  GA03901 Study IV 
TIGR4-3 3  GA07650 Study IV 
TIGR4  4  host strain ATCCa, (356) 
TIGR4-4 4  TIGR4 (378) 
TIGR4-5 5  501 (378) 
TIGR4-6B 6B  NY00216 (360) 
TIGR4-14 14  GA02190 (360) 
TIGR4-19F 19F  GA71 (360) 
TIGR4-23F 23F  TN82328 (378) 
603-1 1  GA02290 (378) 
603-5 5  501 (378) 
603-6B 6B  host strain (231) 
603-14 14  GA02190 (378) 
603-19F 19F  GA71 (378) 
618-6B 6B  host strain Study IV 
618-14 14  GA02190 Study IV 
618-19F 19F  GA71 Study IV 
Donors of the capsule genes 
GA07694 1  TIGR4 ABCb (328) 
GA02290 1  603 ABCb (328) 
GA03901 2  TIGR4 ABCb (328) 
GA07650 3  TIGR4 ABCb (328) 
501 5  TIGR4, 603  (378) 
NY00216 6B  TIGR4 ABCb (328) 
GA02190 14  TIGR4, 603, 618 ABCb (328) 
GA71 19F  TIGR4, 603, 618 (71) 
Table 7 continues 
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Table 7 continues 
Strain Serotype MLST  Source/ reference 
Clinical isolates sharing the same MLST but different serotype 
199-19F 19F 199  (137) 
199-6B 6B 199  (137) 
156-14 14 156  (137) 
156-9V 9V 156  (137) 
156-19F 19F 156  (137) 
162-14 14 162  (137) 
162-9V 9V 162  (137) 
162-19F 19F 162  (137) 
66-23F 9V 66  (137) 
66-9V 23F 66  (137) 
aAmerican Type Culture Collection, Atlanta; bActive Bacterial Core Surveillance of 
Centers for Disease Control and Prevention, Atlanta. 
 
 
4.2 Serum samples 
4.2.1 Sera used in the C3 deposition assay (I-IV) 
Normal human sera (NHS) from adult subjects not immunized with a pneumococcal 
conjugate vaccine were used as a source of complement in the C3 deposition assay. 
Sera collected from 20 young adults were used in studies I and II, and sera from 10 
voluntary adult donors (laboratory personnel) were used in studies III and IV (Table 
8). The ethics committee of the National Public Health Institute, Helsinki, Finland, 
reviewed the protocol and approved the use of the sera. Sera were screened for 
antibodies to the corresponding capsular antigens and relevant protein antigens as 
previously described (338). NHS contained very low concentrations of antibodies to 
capsular polysaccharides, whereas concentrations of antibodies to pneumococcal 
surface proteins, especially to PhtD and PspC, were much higher (Table 8). A serum 
from a healthy adult immunized with PCV (immune human serum, IHS) was also 
used as the source of complement in study II. In studies I, II, and IV, each strain was 
analyzed twice with an agammaglobulinemic human serum (AGS), and in study I 
each strain was analyzed once with a pooled serum from naïve mice (NMS) 
(C57BL/6JRccHsd). Neither AGS nor NMS contained detectable concentrations of 
antibodies to the relevant protein and capsular antigens. All sera were divided into 
small volumes and stored at -70º C to preserve intact complement activity. Once 
thawed, the sample was used immediately as a source of complement for the C3 
deposition assay.  
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Table 8. Concentrations of serum antibody to pneumococcal antigens in normal 
human sera (NHS) used in the C3 deposition assaya 
aGeometric mean IgG concentrations (µg/ml) with 95% confidence interval (CI). 
bN/A, not applicable.  
 
4.2.2 Sera used in the factor H binding assay (I-II) 
In the factor H binding assay, human serum from a healthy, unimmunized adult 
donor was heated at +56º C for 30 minutes to inactivate the heat-labile proteins of 
the complement system. The serum was divided into small aliquots and stored at -
70º C before it was used as a source of factor H. Only one human serum was used in 
the assay; sera from different donors gave identical results in the factor H binding 
assay (data not shown).  
 
4.2.3 Sera used in the opsonophagocytic assay (II-IV) 
The functional activity of anti-capsular antibodies on opsonophagocytosis was 
assessed by analyzing the pneumococcal isolates with sera obtained from infants 
immunized with 4 doses of an 11-valent pneumococcal conjugate vaccine 
Antigen Study I Study II Study III Study IV 
Number of NHS analyzed 
 20 4 8 10 
Antibody to capsular polysaccharidesa 
1 N/Ab N/A 0.48 (0.15-1.46) 0.47 (0.18-1.19) 
2 0.25 (0.14-0.44) N/A N/A 0.63 (0.21-1.89) 
3 0.49 (0.27-0.87) N/A N/A 0.23 (0.67-1.93) 
4 0.11 (0.05-0.23) N/A 0.15 (0.06-0.40) 0.13 (0.06-0.30) 
5 N/A N/A 1.44 (0.44-4.69) 0.86 (0.26-2.82) 
6B N/A 0.16 (0.04-0.76) 0.28 (0.09-0.87) 0.33 (0.14-0.80) 
9V N/A N/A N/A N/A 
14 N/A N/A 0.55 (0.12-2.51) 1.20 (0.23-6.17) 
18C N/A N/A 2.79 (0.95-8.19) N/A 
19F 1.75 (0.85-3.60) 1.79 (0.59-5.40) 1.51 (0.80-2.84) 1.50 (0.93-2.42) 
23F N/A N/A 0.77 (0.31-1.90) 0.79 (0.40-1.56) 
Antibody to surface proteins 
PspC 11.7 (6.87-19.9) 4.68 (0.61-36.1) 12.8 (4.96-32.8) 9.98 (4.45-22.4) 
PhtD 20.1 (14.0-28.8) 12.5 (8.3-18.9) 23.6 (11.3-49.2) 19.9 (10.6-37.6) 
PspA-1 2.03 (1.14-3.64) 1.82 (0.23-14.1) 1.80 (0.77-4.20) 1.60 (0.82-3.12) 
PspA-2 2.08 (1.40-3.08) 2.20 (0.21-22.9) 1.97 (1.08-3.57) 1.98 (1.26-3.10) 
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manufactured by Sanofi Pasteur (394). Written consent was obtained from the 
parents of the children participating in the pneumococcal conjugate vaccine study 
before enrolment. The ethics committee of the National Public Health Institute, 
Helsinki, Finland, reviewed the protocol and approved the use of the sera in this 
study. In study II, each pneumococcal strain was analyzed with 4 to 5 different 
infant sera, and altogether 39 different sera were used. Each strain in study II was 
also analyzed with a control serum with high antibody concentration of serotype-
specific antibodies, drawn from an adult vaccinated with the commercial PCV, 
Prevenar. Pooled sera, collected from the sera of 5 to 11 different infants each, were 
used in studies III and IV. The capsule type-specific antibody concentrations of the 
serum pools (Table 9) were calculated based on concentrations of the individual sera 
previously measured with enzyme immunoassay, EIA (393). 
 
Table 9. Concentrations of antibodies to capsular polysaccharides in the sera 
used in the OPA assaya 
Serotype Low Medium High Study 
1 5.9 (3.2-10.8) 6.6 (5.3-8.1) 14.3 (10.5-19.6) III, IV 
2 NAb NA 12.24c IV 
3 5.0 (2.8-8.7) 5.3 (2.6-10.9) 12.9 (9.7-17.3) III, IV 
4 1.4 (0.8-2.5) 6.2 (3.4-11.3) 14.8 (11.0-19.8) III, IV 
5 1.7 (1.0-2.8) 6.4 (4.6-9.0) 12.9 (8.5-19.6) III, IV 
6B NA 5.8 (3.5-8.1) 59.6d II 
6B 1.2 (0.9-1.5) 5.8 (4.9-7.0) 14.9 (11.1-19.9) III, IV 
14 1.3 (0.7-2.4) 5.8 (3.4-9.8) 10.0 (5.2-19.1) III, IV 
18C 1.2 (0.8-1.8) 4.3 (2.5-7.5) 16.2 (10.0-26.1) III, IV 
19F NA 6.6 (3.2-12) 56.8d II 
19F 5.2 (5.0-5.4) 7.2 (6.6-7.9) 15.5 (13.9-17.4) III, IV 
23F 1.3 (0.7-2.4) 5.8 (3.4-9.8) 10.0 (5.2-19.1) III, IV 
aGeometric mean IgG concentrations (µg/mL) of sera from infants immunized with 
an 11-valent pneumococcal conjugate vaccine, with 95% CI. bNA, not applicable. 
cPneumococcal reference serum Lot 89-SF (287, 288). dOnly one high serum was 
used for analysis. 
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4.3 Bacterial culture conditions 
 
In flow-cytometric assays (C3 deposition and factor H binding), fresh bacterial 
cultures were used and the bacteria were cultured anew for each analysis because 
freezing might have different effects on the bacteria, depending on the strain 
background and serotype. Colonies with an opaque morphology on blood agar plates 
were inoculated into Todd-Hewitt broth supplemented with 0.5% yeast extract, 
THYE (in study II), or THYE supplemented with 5% (heat-inactivated) fetal bovine 
serum, FBS (studies I, III, and IV), and cultured to the early logarithmic growth 
phase to a defined turbidity. In study I, bacteria were cultured twice to the 
logarithmic phase using the first culture as an inoculum. Bacteria were harvested by 
centrifugation, and bacterial concentrations of the cultures were estimated based on 
their optical density from an OD620nm vs. viable count curve. For the 
opsonophagocytic assay bacteria were prepared as described previously (308). In 
short, strains were cultured in THYE broth until the early logarithmic growth phase 
(in study II) or THYE supplemented with 5% FBS (studies II to IV). Glycerol, with 
a final concentration of 15%, was added to the cultures, which were divided into 
aliquots and stored at -70° C. The bacterial concentration of the frozen stocks was 
estimated by plating viable counts. 
 
Culturing the bacteria in liquid medium has been shown to enhance expression of 
genes associated with invasive disease (266). The culture conditions, thus, favored 
opaque colony morphology. Culturing the bacteria in the presence of serum proteins 
in FBS was expected to further enhance expression of virulence factors essential to 
invasive disease. Transcriptional analysis of pneumococci isolated from the blood of 
infected mice has revealed adaptive changes in gene expression compared to 
different growth environments (272). For example, expression on laminin binding 
protein was increased in bacteremia compared to culture in defined semisynthetic 
casein liquid medium supplemented with 0.5% yeast extract (272). A genetic link 
between phtD and laminin binding protein has been reported (274), which suggest 
that the two are co-transcribed.  
 
4.4 Complement C3 deposition assay (I-IV) 
 
The major method used throughout all studies was the complement deposition assay, 
which measures the binding of C3 activation products on pneumococci. The 
bacterial concentrations were adjusted to 109 cells/mL in 20% serum diluted in 
buffer containing Mg2+ and Ca2+ ions in excess (these cations are necessary for the 
function of the classical and alternative complement pathways). A sample of 
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bacteria incubated with serum in buffer containing EDTA, which blocks both the 
alternative and classical pathways of complement activation by binding divalent 
cations, was used as a negative control in each analysis. Bacteria were incubated 
with the serum/buffer for 1 to 30 minutes to allow complement activation and 
opsonization, whereafter unbound serum proteins were washed away. Bound C3 
molecules were detected by fluorescently conjugated antibody, which reacts with 
human C3c and with the C3c part in C3, C3b, and iC3b. The fluorescence intensity 
of the bacterial cells was measured by flow cytometry. Fluorescence intensity higher 
than 10 was considered positive for C3 binding. The percentage of positively 
staining bacteria (%>FL-10) was calculated for each sample in study II. Geometric 
means of fluorescence intensities were compared in studies I, III, and IV.  
 
4.5 Factor H binding to bacterial cells (I-II) 
 
The binding of factor H by pneumococcal cells was also measured by flow 
cytometry. Bacteria (109 cells/mL) were incubated with 30% heat-inactivated serum 
for 30 minutes, after which unbound serum proteins were washed away. The binding 
of factor H was detected by incubating the bacteria for 30 minutes with monoclonal 
murine anti-human factor H antibody 196X (study II) (177) or a commercially 
available antibody (Quidel, study I). The anti-factor H antibody was detected on the 
pneumococci with a secondary antibody that was conjugated to a fluorescent label. 
The geometric mean intensities of fluorescence were analyzed from each sample. 
The binding of factor H from serum was analyzed once in parallel with purified 
human complement factor H, used at a concentration of 90 µg/mL, which roughly 
corresponds to the factor H concentration in 30% human serum. Purified factor H 
and serum gave identical results, as has been reported previously (85).  
 
4.6 Opsonophagocytic assay (II-IV) 
 
The functional activity of serum antibodies against pneumococci was measured by a 
standard opsonophagocytic killing assay (308). The method uses HL-60 cells 
(promyelocytic leukaemia cells, CCL240, American Type Culture Collection, 
Rockville, USA), a human cell line that can be induced, e.g. by dimethyl sulfoxide 
(73), to differentiate into polymorphonuclear-like cells (neutrophil granulocytes) 
(308). The pneumococcal cells (500 colony forming units, cfu) were opsonized with 
serum antibodies in different dilutions, whereafter the polymorphonuclear cells (4 x 
105 cells) were allowed to phagocytose the bacteria in the presence of 12.5% baby 
rabbit serum as source of complement. The assay was performed on microtiter 
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plates, and samples from each well were plated on THYE agar plates. The numbers 
of bacteria (cfu) that remained viable were counted and the results were interpreted 
as the serum antibody concentration that resulted in 50% of bacteria being killed as 
compared to the number of bacteria present in the control well in which only 
complement, but no antibodies, was present (50% reduction of cfu). If a proportion 
higher than 30% of the bacteria were killed by complement, in the absence of serum 
antibodies, the bacterial strain was cultured and analyzed again.  
 
4.7 Statistical methods 
 
Geometric mean fluorescence intensities (GMF) of C3 deposition on bacteria, with 
95% confidence intervals (CI), were compared in studies I, III, and IV, whereas 
study II compared the averages of bacteria positive for C3 deposition with standard 
deviations. In studies I and II, the percentage of fluorescently labeled bacteria 
correlated well with the GMF of C3 deposition (r=0.97 and r=0.98, respectively, 
p<0.001, calculated from log-transformed GMF data). The data of study II were 
analyzed as the GMF of C3 deposition for this thesis. Because all bacterial strains 
bound factor H, GMF, not the percentage of bacteria positive for factor H binding, 
were compared in studies I and II. The geometric means of serum antibody 
concentrations (GMC) required for 50% opsonophagocytic killing with 95% CI 
were calculated in studies II to IV.  
 
The student’s paired t-test was applied on log-transformed data in comparisons of 
wild-type and mutant pneumococci in study I. The student’s t-test was used in 
comparison of serotypes in study II, in comparison of mucosal versus invasive 
isolates and clinical versus reference strains in studies II and III, as well as in 
comparison of capsule donor strains with recipients in study IV. One-way ANOVA, 
followed by Tukey’s HSD (Honestly significant difference) post-hoc test, when 
appropriate, was applied for comparisons of serotypes in study III and for 
comparisons of isolates of the same genotype expressing different capsular serotypes 
or isolates from different genotypes expressing the same capsular serotype in study 
IV. Differences between individual strains within a serotype in studies II to IV were 
likewise compared by one-way ANOVA, followed by Tukey's HSD post-hoc test. 
Pearson’s correlation coefficient was calculated from antibody concentrations 
measured by EIA and from the geometric mean intensities of fluorescence for C3 
deposition of individual NHS in studies I and IV. Pearson’s correlation coefficient 
was also calculated for complement deposition and opsonophagocytic killing using 
geometric means of C3 deposition and antibody concentration in studies III and IV. 
All the above-listed statistical analyses were performed on log-transformed data. 
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Pearson’s correlation was also calculated between serotype-specific C3 deposition 
and the number of hydroxyl groups per polysaccharide, as well as between serotype-
specific mortality of invasive pneumococcal disease (IPD) in patients aged 5 years 
or older (expressed as adjusted OR estimates) and serotype-specific C3 deposition, 
or antibody concentration required for 50% opsonophagocytic killing in study III. In 
all analyses, p-values less than 0.05 were considered to indicate a statistically 
significant difference. 
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5 RESULTS AND DISCUSSION 
5.1 Pneumococcal histidine triad (Pht) proteins may play a 
role in complement resistance of pneumococci (I) 
5.1.1 Lack of Pht proteins resulted in increased C3 deposition on one 
of five pneumococcal strains (I) 
We assessed the influence of Phts on the complement resistance of pneumococci by 
comparing C3 deposition on the surface of wild-type and quadruple Pht-deficient 
mutant strain, which lacked all four Pht proteins (PhtA, PhtB, PhtD, and PhtE). 
Because the genetic background of the strain might affect the outcome, the influence 
of Phts was compared in five different strains. Sera from human donors were used as 
the source of complement in the C3 deposition assay. Antibody to pneumococcal 
antigens, present in NHS, may enhance C3 deposition (265). As antibody to Phts 
could potentially increase C3 deposition on the wild-type, but not the Pht¯ strains, 
we also analyzed C3 deposition using AGS, which did not contain IgG to 
pneumococcal antigens.  
 
The results suggest that Pht proteins could play a role in the complement resistance 
of pneumococci, but the relative importance of these proteins to the virulence of the 
pathogen depends on the genotype of the strain. Only one of the five Pht¯ mutants 
bound significantly more C3 than its wild-type counterpart (Fig. 4). The result was 
the same with NHS and the AGS: deposition of C3 was two-fold on the Pht¯ mutant 
4-CDC compared to the wild-type, but no significant differences were found in C3 
deposition between the wild-type and Pht¯ mutant in any of the other genetic 
backgrounds (Fig. 4).   
 
The relative influence of Pht-deletion, in comparison with deletion of PspA and/or 
PspC, on C3 deposition was assessed by comparing the D39 wild-type strain in 
parallel with the different mutants. We found that the PspA- and PspC-deficient D39 
mutants bound more C3 than the wild-type strain when NHS was used as the source 
of complement, but the differences were not statistically significant. The results 
were similar with the AGS and NHS. Data from previous studies suggest that PspA, 
PspC, and pneumolysin work in concert. The lack of more than one of these proteins 
significantly increases the susceptibility of the strain to complement deposition (213, 
290, 401) and virulence in animal models (268, 290, 401). The findings of this study 
were in concordance with the previous studies, as deposition of C3 was significantly 
increased on the PspA¯PspC¯ double mutant compared to the wild-type D39, but no 
statistically significant differences in C3 deposition could be detected on the Pht¯, 
PspA¯, and PspC¯ single mutants compared to the wild-type D39 strain (Fig. 4).  
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Figure 4. Deposition of complement protein C3 on the pneumococcal surface. 
Wild-type (wt), PhtABDE-quadruple mutant (Pht¯), and PspA¯ and/or PspC¯ 
mutant strains were compared by incubating the bacteria in 20% serum, after which 
deposition of C3 (C3b and iC3b) on the bacterial surface was detected with 
fluorescently labeled anti-C3 antibody and measured by flow cytometry. Each strain 
was analyzed with 6 (D39 strains) or 20 (all other strains) different normal human 
sera (NHS). A single analysis was performed with an agammaglobulinemic serum 
(AGS). Serum with 10 mM EDTA, which inhibits activation of complement via 
classical and alternative pathways, was used as a negative control. Geometric mean 
intensities of fluorescence (GMF) with 95% confidence intarvals are shown. 
***p<0.001 (comparison of mutant with the corresponding wt strain by student’s 
paired t-test, 2-tailed). The data originates from Fig. 4 and Fig. 5 of I. 
 
In contrast to the results of this thesis, Ogunniyi et al. (2009) reported increased C3 
deposition on the Pht¯ mutant D39 (269). One important difference in their methods 
compared to the present study was that they used mouse serum as the source of 
complement. Because no significant increase in complement deposition on the Pht¯ 
mutant D39 was seen with human sera, the strains of this study were also analyzed 
with a pooled serum from mice. The murine serum gave results similar to those 
observed with the human sera: increased C3 deposition was measured on the Pht¯ 
mutant 4-CDC and PspA¯PspC¯ mutant D39, but not on the Pht¯ mutant D39 (Fig. 
5B of I). To confirm that deletion of Phts did not affect expression of other 
pneumococcal proteins, which could affect the complement resistance of the strains, 
expression of PspA and PspC on the surface of the pneumococcal strains was 
measured by flow cytometry. No significant differences in the surface expression of 
PspA or PspC were observed between the wild-type and Pht¯ strains. Ogunniyi et al. 
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(2009) confirmed, by using real-time RT-PCR, that deletion of any given pht gene 
had no effect on the level of transcription of any of the remaining pht genes (269), 
and that deletion of the suggested promoter region of the pht genes did not affect 
mRNA transcription of genes for PspC, PsaA, and pneumolysin, whereas 
transcription of pspA was three-fold lower in the adcR mutant (269). However, they 
did not mention if transcription or expression of PspA and PspC by the quadruple 
Pht mutant was characterized. It is possible that reduced expression of either PspA 
or PspC could have made their quadruple Pht¯ mutant D39 strain more susceptible 
to complement.  
 
It is possible that the genotype of the strains, rather than allelic variation of Pht 
proteins, partly explains why the lack of Phts affected complement resistance of one 
but not all of the studied strains. The lack of PspC impaired complement resistance 
of several but not all studied pneumococcal strains suggesting that allelic variation 
in PspC structure may affect its interaction with the complement system (402). The 
PspC family is heterogenic and different functions have been suggested for the 
alleles (164). For example, a particular allele has been associated with C4bp binding 
(89). The role of PspA in complement resistance of pneumococci has only been 
studied in two genetic backgrounds, D39 and WU2, where C3 deposition was 
increased on the PspA¯ mutants compared with the respective wild-type strains 
(298, 365). Both PspA family 1 and family 2 proteins could inhibit C3 deposition on 
the WU2 strain (298). In contrast to PspC and PspA, the genes encoding Pht 
proteins are conserved (2, 131). Therefore, allelic differences in the Pht protein 
function are unlikely. 
 
The efficacy of antibody-mediated protection has been shown to depend on the 
genotype of the challenge strains (2, 145, 306). PspA and PspC immunizations were 
efficient in protecting mice against challenge with the homologous pneumococcal 
strain D39, but vaccination with these antigens afforded little or no protection 
against a heterologous challenge with the 3-43 (serotype 3) and 4-CDC (serotype 4) 
strains (119). Previous studies have implied that the protection of immunized mice 
seems to be limited to the same PspA family (242, 306). It was suggested that allelic 
variation in the PspA and PspC molecules of the challenge strains could explain the 
different outcomes (119). Indeed, the PspA of D39 belongs to family 1 whereas 
strains 3-43 and 4-CDC have genes for family 2 PspA (119). The absence of 
protection by antibody to PspC against the 3-43 strain was understandable since this 
strain has a hic allele (PspC11) (169), which diverges from the PspC allele of D39. 
Previous studies reported that immunization with PhtB and PhtE protects mice 
against sepsis caused by WU2 and another serotype 3 strain (131), but not against 
D39 (268). Immunization with PhtD seemed to afford cross-protection against 
challenge by D39 as well as 3-43 and 4-CDC (119), which could be related to the 
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fact that PhtD is well conserved across pneumococcal strains (302). However, mice 
immunized with PhtA or PhtD were not protected against challenge with the 
homologous and highly virulent strain N4 (2). Similarly, immunization with PspA 
protected mice better from WU2 than from the homologous serotype 4 strain 
EF5668 (145). Passive immunization of mice with anti-PhtA antiserum afforded 
efficient protection against EF5668, which could indicate that Pht-proteins are more 
important than PspA to the virulence of EF5668 (2). We found that the serum 
antibody concentration to PspA correlated positively with C3 deposition on all the 
encapsulated wild-type strains except 4-CDC, whereas antibody to PhtD correlated 
positively, although weakly, with only 4-CDC. Since deletion of Pht proteins from 
D39 did not affect the susceptibility of D39 to complement, it is possible that the 
importance of Pht proteins in the D39 genotype is not as significant as it seems to be 
in genotype 4-CDC.  
 
It would be interesting to compare how (or if) deletion of PspA or PspC would have 
affected on C3 deposition on the 4-CDC strain. Although lack of Phts increased C3 
deposition on only one of the five strains, it is possible that deletion of PspA, PspC, 
or pneumolysin from the Pht¯ mutants would have resulted in a synergistic effect on 
the susceptibility of the strains to C3 deposition. Also, deletion of Pht proteins from 
the EF5668 and other serotype 4 strains, as well as capsule switching of 4-CDC, 
would have been useful in the assessment of whether the serotype could be one 
factor affecting the role of Pht proteins to the strain. Because the genotype of the 
pneumococcal strain can have a significant influence on its virulence, it is important 
to study the effects of virulence factors using multiple, heterogeneous strains.  
 
5.1.2  Pht proteins do not inhibit complement by binding factor H (I) 
Factor H is a fluid-phase complement regulator, which pathogenic streptococci are 
capable of binding in a functionally active form, thus inhibiting C3 deposition on 
their surfaces (172). PspC has been shown to bind factor H and thus contribute to the 
ability of the bacterium to evade complement attack and opsonophagocytosis (84, 
169, 170, 256). The PspC protein found in serotype 3 pneumococci, Hic, was first 
identified on the basis of its ability to inhibit complement activation by recruiting 
factor H on the bacterial surface (169, 170). The affinity of the PspC of S. 
pneumoniae D39 to factor H was later shown to be 23-fold stronger compared to Hic 
(220). In a previous study D39 was reported to bind mouse factor H, although to a 
lesser extent than human factor H (289). More recent studies have indicated that the 
interaction of PspC with factor H is species specific; clinical isolates bound only 
human factor H, not murine or any other factor H that were tested (rat, rabbit, horse 
or bovine) (221). Therefore it is not surprising that in mouse models of invasive 
disease the lack of PspC had little, if any, effect on strain virulence (30, 270, 271). 
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In line with the observation that factor H binding by PspC is species-specific, we 
found that the PspC¯ mutant D39 was equally resistant to C3 deposition as the wild-
type when murine serum was used as source of complement, whereas with human 
sera (NHS and AGS) more C3 was deposition on the PspC¯ mutant compared to 
wild-type, although the difference was not significant. 
 
To study the potential mechanism how Pht proteins could inhibit C3 deposition on 
pneumococci, different methods were used to measure potential binding of factor H, 
by pneumococcal strains or purified Pht antigens. Analysis of bacterial cell lysates 
with an overlay assay indicated that factor H binds specifically to the bands 
corresponding to the molecular size of PspC proteins (Fig. 6C of I). The size of 
PspCs ranges from 59 to 105 kDa (e.g. the PspC allele of D39 is a 75 kDa protein) 
(310), whereas PhtA, PhtB, PhtD and PhtE have molecular masses of approximately 
92, 93, 94 and 115 kDa, respectively (2). Mutants lacking Phts exhibited factor H 
binding patterns identical to the wild-type strains, whereas PspC¯ mutants bound no 
factor H (Fig. 6C of I).  In the enzyme immunoassay the Pht antigens (PhtA, PhtB, 
PhtD and PhtE) did not bind factor H, whereas PspC was a strong binder of factor H 
(Fig. 6A of I). Flow cytometric analysis of factor H binding to pneumococcal cells 
further highlighted the importance of PspC for factor H binding, as no factor H 
binding was measured on the PspC¯ mutant. All wild-type strains bound factor H 
and the lack of Pht proteins did not influence this interaction (Fig. 5). The Pht 
mutant 4-CDC strain bound factor H slightly but significantly less than the parent 
strain, whereas the D39 Pht mutant bound slightly but also significantly more than 
the wild-type. However, the difference between wild-type and Pht¯ mutant 4-CDC 
was very small, and compared to the PspC¯ mutant, it was still a strong binder of 
factor H. Ogunniyi et al (2009) reported that Pht proteins evade complement 
deposition in a similar mechanism as PspC and that Pht antigens would bind factor 
H (269). The finding by Ogunniyi et al. (2009) is controversial, as they used murine 
serum as source of complement, and clinical pneumococcal isolates have previously 
been reported to bind only human factor H (221). Furthermore, factor H binding is 
known to be almost completely dependent on PspC (402). The fact that direct 
binding of factor H to purified Pht antigens or Pht proteins in pneumococcal cell 
lysates was not seen in this study argues that factor H binding is not the main 
function of these proteins. Several different virulence functions in addition to 
complement inhibition have been reported for PspA and PspC. It is likely that Phts, 
too, have other attributes and their main virulence mechanism could be other than 
complement inhibition. 
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Figure 5. Binding of factor H to wild-type (wt), PhtABDE- quadruple mutant 
(Pht¯) and PspA¯ and PspC¯ mutant pneumococcal strains were analyzed by 
incubating the bacteria in heat-inactivated 30% human serum, after which binding of 
factor H to the bacterial cells was detected with fluorescently labeled antibody and 
measured by flow cytometry. Geometric mean intensities of fluorescence (GMF) 
from 3 repeated analyses with 95% CI are shown. *p<0.05, **p<0.01, ***p<0.001 
(comparison with the corresponding wild-type by Student’s paired t-test, 2-tailed). 
The data originates from Fig. 6B of I. 
 
 
5.2 The different abilities of capsular serotypes to resist 
complement deposition affect their susceptibility to 
phagocytic killing (II-IV) 
 
The outcomes of conjugate vaccine trials suggest that protection provided by 
immunization is suboptimal against serotypes 1 and 19F in invasive disease (79, 
321, 387) and against AOM caused by 19F (33, 103, 187, 286). To find out reasons 
for the lower efficacy of conjugate vaccines to certain serotypes, we compared the 
ability of pneumococcal serotypes to resist opsonophagocytic killing and 
complement deposition and explored whether the amount of C3 deposited on the 
surface of the bacterium reflects its sensitivity to opsonophagocytosis. Several 
clinical isolates representing each capsular serotype were analyzed. The relative 
influence of the capsular serotype, compared to the strain background, on 
opsonophagocytic killing and C3 deposition was further evaluated by comparing 
isolates which share the same genotype but express different capsule types. Isogenic 
capsule-switched mutants and natural capsule switch variants of the same 
pneumococcal strain (which share the same MLST) were compared.  
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5.2.1 The capsule affects phagocytic killing (II-IV) 
In the opsonophagocytic assay the concentration of antibodies required for killing 
pneumococci varied depending on the capsular serotype (Fig. 6a, b). A six-fold 
concentration of capsule antibodies was required for killing of serotype 19F clinical 
isolates compared to 6B isolates. Also, killing of clinical isolates of serotypes 1 and 
5 required a significantly higher anti-capsular antibody concentration compared to 
serotype 23F. The antibody concentrations required for opsonophagocytosis in 
studies II (6B and 19F isolates) and III (other clinically relevant serotypes) cannot 
be directly compared because the studies used different serum sources and because 
the long term reproducibility of the assay is not optimal. To assess the sensitivity of 
serotypes 6B and 19F relative to other serotypes, reference strains of the 
opsonophagocytic assay were analyzed. Serotype 19F reference strain required a  
three-fold concentration of capsule antibodies compared to the serotype 1 and 5 
reference strains for opsonophagocytic killing. This indicated that serotype 19F was 
the most resistant of the serotypes. There was little variation in the sensitivity to 
opsonophagocytosis between clinical isolates within serotypes, suggesting that the 
capsule type could be more important than the genotype for determining resistance 
to opsonophagocytosis. This finding was further supported by the observation that 
the concentration of anti-capsule antibodies required for killing isogenic strains or 
clinical isolates sharing the same genotype depended more on the capsule type they 
expressed and less on the genotype (Fig. 6c,d). Irrespective of the strain background, 
serotypes 1 and 19F required the highest concentrations of anti-capsular antibodies 
for opsonophagocytosis. The results clearly indicate that the concentration of type-
specific antibodies required for opsonophagocytic killing is linked to the capsule 
type. 
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Figure 6. Opsonophagocytic killing of pneumococci. The sensitivity of 
pneumococcal isolates to opsonophagocytic killing was assessed by allowing human 
HL-60 granlulocytic cells to phagocytose pneumococci after pre-opsonization of the 
bacteria in the presence of complement and sera from humans immunized with a 
pneumococcal conjugate vaccine. Clinical isolates (A, B), strains which share the 
same genetic background (genotype) and express different capsules (C) and clinical 
isolates which are clonally related (have the same MLST) but express different 
capsules (D) were compared. Opsonophagocytosis is expressed as the serotype-
specific geometric mean antibody concentration required for 50% opsonophagocytic 
killing; 95% confidence intervals are given. Serotypes marked with an asterisk (in 
panel B) were analyzed in a different study than the other clinical isolates and the 
results of the opsonophagocytic killing assay are not directly comparable across the 
two studies. The data originates from Fig. 2A in III (panel A), Fig 1B in II (panel B) 
and Fig. 4B and 4C in IV (panels C and D, respectively). 
 
Data from clinical trials demonstrate a correlation of serotype-specific vaccine 
efficacy with opsonophagocytic activity of the antibodies (98, 329). In our studies 
serotype 1 and 19F isolates required high concentrations of capsule-specific 
antibodies for opsonophagocytosis, which is in concordance with their less optimal 
vaccine efficacies. However, in The Gambia the conjugate vaccine offered a good 
protection against invasive pneumococcal disease caused by serotype 5 (321), yet in 
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our study it required the highest concentration of capsule antibodies for killing in 
OPA. It has been proposed that the minimum antibody concentration after the 
primary immunization series associated with long term protection against invasive 
disease would be in the range of 0.15 to 0.5 μg/mL (33). A meta-analysis of three 
clinical trials derived a protective concentration of 0.35 μg/mL for anticapsular 
antibodies to the serotypes of a licensed 7-valent pneumococcal vaccine (174). This 
concentration has been recommended by a WHO Working Group as applicable on a 
global basis for assessing the efficacy of future pneumococcal conjugate vaccines. In 
this thesis several clinical isolates were analyzed side by side with the reference 
strains used in the OPA assay, which confirmed the previous finding that up to 5 
times higher geometric mean antibody concentration is required for 
opsonophagocytic killing of serotype 19F than 6B pneumococci (98, 329, 394). 
Serotype 1 and 5 clinical isolates were even more resistant to opsonophagocytic 
killing than those of serotype 19F. In line with the findings of this study, the 
geometric mean OPA titers of children immunized with the 13-valent pneumococcal 
vaccine were lower for serotypes 1 and 5 compared to the serotypes, other than 19F, 
of the 7-valent vaccine (59, 104, 185, 395). This data strongly suggests that a higher 
concentration of capsule antibodies may be required for protection from disease 
caused by some serotypes. The different susceptibilities of different serotypes to 
opsonophagocytosis and antibody-mediated protection should be taken into account 
when guidelines for serological correlates for vaccine efficacy evaluations are made.  
 
5.2.2 The capsule affects complement resistance (II-IV) 
In the complement assay deposition of C3 on the bacteria was studied by using 
intact human sera as the source of complement. In the initial analyses I compared C3 
deposition on serotype 6B and 19F isolates allowing the activation of complement to 
occur for 1 and 5 minutes. Already after 1 minute incubation more C3 was bound on 
serotype 6B than 19F isolates. The difference increased after 5 minutes of 
incubation (Fig. 7), by which time C3 deposition had already reached a plateau. It 
was observed that complement activation was, predictably, a rapid process and 
prolonging the incubation time up to 30 minutes did not markedly enhance C3 
deposition or alter the result. Therefore, in the comparison of pneumococcal 
serotypes, bacteria were incubated with the serum for 5 minutes. 
 
THL 2011 – Research 58 71 
Interplay of Virulence Factors 
in Complement Resistance of 
Streptococcus pneumoniae 
 
 
Figure 7. C3 deposition on clinical isolates of serotypes 6B and 19F. Bacteria 
were incubated with an agammaglobulinemic serum (AGS) and four different 
normal human sera (NHS) for 1 or 5 minutes. Deposition of C3 (C3b and iC3b) on 
the bacterial surface was detected with a fluorescently labeled anti-C3 antibody and 
measured by flow cytometry. Differences between serotypes were statistically 
significant after 5 minutes of incubation. *p<0.05, **p<0.01, ***p<0.001, Student’s 
t-test. Data originates from Fig. 4 of II. The results after 1 minute of incubation have 
not been previously published. 
 
 
The comparison of several other clinical isolates revealed significant differences 
between serotypes in resistance to C3 deposition (Fig. 8a). Serotype 6B was more 
sensitive and serotype 1 more resistant to C3 deposition than any of the other 
serotypes. The clinical isolates within serotypes 1, 14, 23F, and 18C varied 
significantly in sensitivity to complement, indicating the significance of serotype 
independent features of the isolates in their resistance to complement. It was found 
that the isolates expressing different capsular serotypes differed significantly in their 
resistance to complement deposition, but differences between genotypes or MLSTs 
were much smaller than the differences between serotypes (Fig. 8b, c). In 
combination with any genetic background serotype 19F was always the most 
resistant capsule type. The concentration of anti-capsular antibodies present in the 
NHS was higher against 19F than against most other serotypes (Table 2), indicating 
that a low concentration of antibodies against 19F polysaccharide does not explain 
the complement resistance of serotype 19F isolates.  
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Figure 8. C3 deposition on pneumococci was measured by incubating the bacteria 
in 20% serum, after which deposition of C3 (C3b and iC3b) on the bacterial surface 
was detected with fluorescently labeled anti-C3 antibody and measured by flow 
cytometry. Clinical isolates (A), strains which share the same genetic background 
(genotype) and express different capsules (B) and clinical isolates, which are 
clonally related (have the same MLST) but express different capsules (C) were 
compared. Serotypes marked with an asterisk were analyzed in a different study than 
the other serotypes in panel A. Geometric mean intensities of fluorescence (GMF) 
are shown with 95% CI. NHS, normal human sera; AGS, agammaglobulinemic 
serum. Each isolate was analysed with ten different NHS and once with the AGS. 
AGS results have not been previously published. Data presented in panel A 
originates from Fig. 1A of III and data in panels B and C from Fig. 2B and 2C of IV.  
 
The pneumococcal teichoic acid, also known as C-polysaccharide (C-PS), is a cell 
wall component common to all pneumococci, which binds serum C-reactive protein 
(CRP) (390). CRP has been shown to bind to several strains of S. pneumoniae 
including serotypes 3, 4, 6, 14, 19, 23 and 27, and the unencapsulated strain R36A 
(244). The opaque phenotype expresses less C-PS compared with the transparent 
form (379). CRP bound to pneumococci binds to C1q and activates the classical 
pathway of complement (313). CRP-mediated complement activation is restricted to 
the early part of the pathway, which generates opsonins that target the CRP-bound 
substances for opsonophagocytosis (28). Surface bound CRP reduces deposition of 
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C3b as a result of recruitment of factor H (171, 243) and C4BP which competes with 
C1q for binding to CRP (340). The ability of CRP to recruit factor H during 
complement activation has been suggested to support opsonic activation of 
complement without contributing further to the inflammatory state (244). For the 
analyses of this thesis, the bacteria were cultured in liquid medium, which has been 
shown to favor opaque colony morphology (266). The level of C-PS expression by 
the pneumococcal strains was not measured, but since they were all cultured with 
the same method, differential expression of C-PS by different serotypes, due to a 
different phase, is unlikely to explain the differences observed between the serotypes 
in resistance to C3 deposition. Moreover, the differences in C3 deposition between 
the serotypes were observed also between capsule-switch mutants that share 
otherwise the same genetic background. CRP is an acute phase serum protein, which 
only increases dramatically in concentration during inflammation. In healthy young 
adult volunteer blood donors, the median concentration of CRP is 0.8 μg/mL but 
during inflammation or tissue injury it may rise up to 500 μg/mL (70, 282). The sera 
used in the C3 deposition assay were collected from healthy young adults. The 
concentration of CRP in the sera was not measured, but because each strain in the 
same study was analyzed with the same set of sera, the CRP level in the sera should 
not affect the ultimate result. 
 
Significant correlations were found between complement deposition and serum 
antibody concentration to pneumococcal surface proteins (PspA, PspC, and PhtD) in 
the normal human sera, whereas antibody concentrations to only a few capsule 
serotypes correlated with C3 deposition. Hierarchies of complement activation have 
indicated that IgG1 along with IgG3 is the most potent subclasses at mediating 
activation of the complement cascade, while IgG2 is a very poor activator (62). 
IgG2 is the dominating IgG subtype in response to pneumococcal capsular 
polysaccharides (24). Complement deposition was increased when the complement 
source was serum from an individual immunized with a conjugate vaccine. This 
suggested that C3 deposition was also dependent on the concentration of anti-
capsular antibodies. Immunization with a conjugate vaccine has been reported to 
alter the ratio of IgG2 to IgG1 by inducing a higher proportion of IgG1 (347). The 
percentage of bacteria positive for C3 binding was similar with 6B and 19F when 
the bacteria were incubated with immune serum containing a three-fold antibody 
concentration to 19F compared to 6B. However, even though antibodies to capsular 
polysaccharides clearly enhanced C3 deposition, they did not even out the difference 
in C3 deposition between the two serotypes, when the geometric mean intensities of 
fluorescence were compared. The polarization of serotypes in susceptibility to C3 
deposition was evident also when the source of complement was an 
agammaglobulinemic serum (Fig. 8).  
 
THL 2011 – Research 58 74 
Interplay of Virulence Factors 
in Complement Resistance of 
Streptococcus pneumoniae 
 
The early studies of Hostetter, performed by immunoblotting, suggested that the 
ratio of the iC3b to C3d (both degradation fragments of C3b) rather than the total 
amount of C3 deposited on pneumococci would explain differences between 
serotypes in resistance to opsonophagocytosis, because the most important 
complement receptor, CR3, recognizes iC3b, but not C3d (156). At the beginning of 
this study, I measured the relationship of C3b binding and its degradation to iC3b by 
EIA and visualized the degradation of C3 fragments on serotype 6B and 19F isolates 
by immunoblotting using methods described previously (170). The very first 
(unpublished) results suggested that serotype 19F strains could degrade C3 more 
efficiently, but as the analyses were repeated, it was found that the reproducibility of 
the assays was not good. In flow cytometric analysis of C3 deposition, a clear 
association was found between the total amount of C3 detected on the bacterial 
surface and sensitivity to opsonophagocytosis, which is in contrast to Hostetter’s 
hypothesis. Several bacterial pathogens have been shown to favor the inactivation of 
C3b to iC3b, e.g. by sialylation of capsular polysaccharides and by employment of 
factor H on the bacterial surface (201). Rapid cleavage of C3b to iC3b is favorable 
to the pathogen, as it prevents formation of new convertases and thereby inhibits 
deposition of new C3b molecules on the bacterial surface. Rapid breakdown of C3b 
to iC3b, thus, results in a decreased net C3 deposition.  
 
There was no difference in complement deposition between mucosal and invasive 
isolates of the same serotype. In contrast to our finding, Sabharwal et al. (2009) 
observed that serotype 6A strains isolated from invasive infections were less 
susceptible to C3 deposition than strains of the same serotype isolated from the 
nasopharynx (322). Factor H binding by pneumococci is mostly mediated by PspC 
(402). Quin et al. (2006) reported that carriage isolates recruited significantly more 
factor H to their surfaces than either systemic or mucosal isolates. This binding was 
independent of the capsular serotype (291). Yuste et al. (2010) found that there was 
no significant correlation between the degree of factor H binding to pneumococcal 
strains and the effects of loss of PspC on C3 deposition (402). This suggested that 
there is no obvious association between the quantity of factor H on the bacterial 
surface and effects on complement deposition. In this study, all serotype 6B and 19F 
clinical isolates bound factor H, but there was no correlation between C3 deposition 
and factor H binding. This is in line with the previous studies and indicates that the 
differences in the efficiency of factor H binding could not account for the serotype-
related differences seen in complement resistance. The differences observed in C3 
deposition between serotypes, but not between genotypes, most likely result from 
the polysaccharide capsule, which is the most important factor contributing to the 
complement resistance of pneumococci. 
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Hyams et al. (2010) reported large differences in C3 deposition on opaque-phase 
variants of TIGR4 expressing serotype 4, 6A, 7F, and 23F capsules, even though the 
thicknesses of the capsule layers were similar (163). Timely regulation of capsule 
expression could be more important than its thickness to the ability of pneumococci 
to colonize and cause invasive disease. At the early stages of colonization, the 
capsule inhibits trapping of the pathogen to the luminal mucus and clearance by 
mucociliary flow (258). On the epithelial side of the mucus, a reduced amount of 
capsule promotes colonization by exposing adhesins and strengthening intimate 
contact with the epithelial cells (135). Once invasive disease is established, heavily 
encapsulated bacteria are better protected from phagocytes (189). It is believed that 
the net charge of each serotype, as well as the chemical composition, is the central 
reason for their virulence. Most capsule serotypes are highly charged at 
physiological pH, and this can directly interfere with interactions with phagocytes 
(207). To explain the differences observed between serotypes in resistance to C3 
deposition, I looked for potential differences in the number of available targets for 
C3 deposition in the capsular polysaccharides, based on their published chemical 
compositions (191). Activated C3 forms a covalent bond with hydroxyl and amino 
groups on biological targets, via an acyl group. A significant association was found 
between the numbers of hydroxyl groups per polysaccharide repeat unit and 
complement deposition on the serotype: a high number of free hydroxyl groups was 
associated with increased C3 deposition (Fig. 5B of III). It was found that the 
serotypes 1 and 5, which were the most resistant to C3 opsonization, have a smaller 
number of targets (-OH or -NH2 groups) available for C3b to make ester or amide 
linkages than for example serotypes 6B and 23F (examples shown in Fig. 9). These 
groups are also more often acetylated on serotypes resistant to C3 deposition than 
the targets on serotypes which are less resistant to C3 deposition. Thus, a low 
number of targets available for complement deposition and the presence of acetyl 
groups in the amino and carboxyl groups of the sugars of the capsule polysaccharide 
seem to be advantageous to resisting recognition by innate immune mechanisms. 
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Figure 9. Repeating unit structures of the serotype 1 and 6B pneumococcal 
polysaccharides. Sug1, 2-acetamido-4-amino-2,4,6-trideoxy-d-galactose; Gal, 
galactose; Glc, glucose; Rha, rhamnose. Reproduced from (191) with the permission 
of the copyright holder, Elsevier Inc. In the repeating sugar unit of serotype 1 there 
are 6 hydroxyls, of which three are in acidic carboxyls, and one of the two amino 
groups is acetylated. In comparison, serotype 6B has 11 hydroxyls, none of them in 
carboxylic acids and there is no acetylation. 
 
5.2.3 Resistance to complement deposition is associated with 
decreased susceptibility to opsonophagocytic killing (II-IV) 
It is well-known that neutrophil phagocytosis is markedly increased by opsonization 
of pneumococcus with complement (404). In a study by Hyams et al. (2010), 
complement deposition on isogenic TIGR4 mutants expressing different serotypes 
correlated with neutrophil phagocytosis in the presence of complement, but 
differences in phagocytosis between strains were abolished when the bacteria were not 
opsonized (163). Antibodies activate the classical pathway of complement and, thus, 
enhance opsonophagocytosis. On the other hand, the importance of phagocytosis 
mediated by Fc receptors seems to be less important for protection against 
pneumococcal infection (323). Killing in the opsonophagocytic assay, applied in the 
studies of this thesis, is strongly mediated by complement and complement receptors. 
The polymorphonuclear HL-60 cells used in the assay express complement receptors 
CR1 and CR3 (for C3b and iC3b) and a low-affinity receptor FcRII for IgG (308).  
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It was found that the pneumococcal serotypes which required a higher concentration 
of anti-capsular antibody for opsonophagocytic killing, were also among the 
serotypes least susceptible to opsonization with C3b (Fig. 10). Serotype 1 was 
especially resistant to complement, which could be one explanation for the poor 
efficacy of conjugate vaccines to invasive disease caused by this serotype (79, 321). 
In contrast, serotype 6B was consistently the most susceptible serotype to C3 
deposition. This might explain why the conjugate vaccine was found to be 
efficacious in protection against AOM caused by 6B at a relatively low antibody 
concentration (176). Differences between serotypes in sensitivity to 
opsonophagocytosis could result not only from the amount of complement 
deposited, but also from the type of exposure of complement to the phagocytes due 
to the different capsular structures and localization of the opsonins. 
 
The difference in sensitivity to complement deposition is not likely to be the only 
factor explaining the different susceptibilities of the serotypes to opsonophagocytic 
killing. Despite moderate resistance to complement deposition, a very high 
concentration of serotype-specific antibodies was found to be required for 
opsonophagocytosis of serotype 19F strains, suggesting inferior functional 
properties of antibodies. In a previous study, the correlation of antibody 
concentration and avidity was compared with opsonophagocytic activity, and it was 
found that the concentration of specific antibodies to serotype 6B and 19F 
polysaccharides is distinctly the most important factor contributing to 
opsonophagocytic killing, whereas no significant contribution of antibody avidity 
was found (10). The results nevertheless suggested a statistically non-significant 
trend that less antibodies of high avidity than low avidity were needed for killing 
bacteria. In later studies, no such association could be demonstrated (98, 393). It is 
possible that high-avidity antibodies more strongly enhance complement deposition 
than weak-avidity antibodies. The serum antibody concentration affects both 
opsonophagocytic killing and complement deposition. These two measures seem to 
be linked, but the role of antibody avidity in the process remains unclear.  
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Figure 10. Correlation between complement deposition and OPA killing. 
Pneumococcal isolates representing different capsular serotypes and genotypes were 
compared; clinical isolates (A, B), pneumococcal reference strains (C), and strains 
that expressed different capsular serotypes in the same genotype and the capsule 
donor strains (D). Geometric mean intensities of fluorescence (GMF) corresponding 
to C3 deposition and geometric mean anti-capsular antibody concentrations required 
for 50% opsonophagocytic killing of pneumococci are shown. The serotypes, which 
were the most resistant to C3 deposition, required the highest concentration of 
serotype-specific capsule antibodies for opsonophagocytic killing. Statistically 
significant correlations are marked with an asterisk (Pearson’s correlation 
coefficient), *p<0.05, **p<0.01. Data in panels B and C originates from Fig. 3A and 
3B from III. Previously unpulished data is presented in panels A and D. 
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5.3 Resistance to complement and opsonophagocytic killing 
is associated with serotype-specific mortality in invasive 
pneumococcal disease (III-IV) 
 
Considering the extent of exposure to pneumococci, invasive disease is rare and a 
number of virulence factors influence the success of pneumococcal isolates to transit 
from nasopharyngeal carriage to causing invasive disease (144). The capsular 
serotype is assumed to be more important than the genotype for the ability of 
pneumococcus to cause invasive disease (54, 56, 137). The invasive disease 
potential is a measure of the ability of pneumococci to progress from 
nasopharyngeal carriage to invasive disease. It is estimated by comparing 
nasopharyngeal carriage rates of pneumococcal serotypes (or strains) with their rates 
in invasive pneumococcal disease (IPD) (54). This is similar to the attack rate, 
which is the risk of disease as a result of pathogen acquisition (54, 342). Certain 
serotypes, such as 1, 4, 5, 7F, and 14, appear to be associated with invasive disease, 
whereas some serotypes, such as 6B, 19F and 23F, have a low invasive disease 
potential although they also occasionally cause invasive disease (54, 56, 137, 200, 
320, 332, 342). 
 
Invasiveness of pneumococcal serotypes is not equivalent to their virulence 
(mortality). Mortality following IPD caused by different serotypes was assessed in a 
large population-based study by Harboe et al. (2009), by using a multivariate logistic 
regression analysis, in which odds-ratio estimates were calculated for the most 
frequent serotypes (138). A case was defined as an occurrence of IPD confirmed by 
positive culture for S. pneumoniae from a hospitalized patient’s cerebrospinal fluid 
or blood. The OR estimates were adjusted for age, sex, time at diagnosis, IPD focus 
(bacteremia or meningitis), alcoholism-related conditions and low, medium or high 
comorbidity score and ORs were calculated for serotypes ≥ 50 IPD cases only (138). 
In patients older than 5 years, certain serotypes, e.g. 3 and 19F, were found to have a 
highly increased mortality as compared with serotype 1. In children younger than 5 
years of age, serotypes 14, 6A, 7F, and 4 tended to be associated with a decreased 
mortality.  
 
The higher mortality noted with opportunistic serotypes might be determined by 
host rather than by pathogen-derived factors. Pneumococcus tends to infect patients 
with an impaired immune system, and this behavior seems to be even more 
pronounced for opportunistic serotypes. Previous studies have indicated that highly 
invasive serotypes, such as 1, 7F and 14, are associated with lower mortality 
proportions and are more likely to be invasive in younger patients who have fewer 
comorbid conditions (341). In another meta-analysis of serotype-specific disease 
outcomes, significant differences were found in the risk ratio estimates among 
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serotypes in patients with bacteremic pneumonia (377). Weinberger et al. (2010) 
concluded that the serotypes with an increased risk of death (3, 6A, 6B, 9N, and 
19F) had high carriage prevalence and low invasiveness (377), whereas serotypes 1, 
7F, and 8 were associated with a decreased risk of death (377). It has been suggested 
that capsular serotypes, which are carried for a short duration and have a high attack 
rate, such as serotypes 1, 5, and 7F, which affect previously healthy individuals and 
are associated with lower mortality, behave like “primary pathogens” (342). 
Meanwhile, serotypes that are carried for a long duration, and which have a low 
invasive disease potential, such as 6B, 19F, and 23F, behave like opportunistic 
pathogens, causing disease in patients with an underlying condition and are 
associated with a more severe disease and higher mortality (138, 341).  
 
In this thesis, I found a serotype-related relationship between the severity of IPD, 
described by Harboe et al. (2009) (138), and resistance to C3 deposition and 
opsonophagocytic killing (Fig. 11). This suggests that the primary pathogens, which 
are associated with a lower mortality than the opportunistic serotypes, are more 
resistant to C3 deposition and require a higher concentration of capsule antibodies 
for opsonophagocytic killing. Despite the importance of capsular serotype as a 
determinant of invasiveness, clinical pneumococcal isolates belonging to different 
MLSTs have been found to have different invasive disease potentials (137). It was 
possible to detect a trend for serotype-specific correlation between IPD mortality 
and resistance to complement and opsonophagocytosis not only with clinical 
isolates, but also with capsule-switched mutants and strains that share the same 
MLST and express different capsules (Fig. 11). Serotypes 3 and 19F are relatively 
resistant to complement and require an exceptionally high concentration of 
antibodies for killing, yet their IPD mortalities are notably high. If these two 
serotypes were excluded from the statistical analysis, the correlations reached 
statistical significance (Fig. 11). Because the complement system and phagocytosis 
have central roles in systemic immunity to S. pneumoniae, the differences observed 
between pneumococcal serotypes in the ability to cause invasive disease may reflect 
the relative capacity of the serotypes to activate innate immune responses. The 
correlation of serotype-specific complement resistance with IPD severity may 
indicate that primary pathogens, which are able to cause disease in healthy 
individuals and have a high potential to cause invasive disease (54, 56, 327, 341), 
are better able to resist host immunity than the opportunistic serotypes.  
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Figure 11. Correlation between serotype-specific mortality to invasive 
pneumococcal disease (IPD), C3 deposition, and OPA killing. Pneumococcal 
isolates representing different serotypes and genotypes were compared; clinical 
isolates and reference strains (A, B) and isogenic strains expressing different 
capsules in the same genotype and the capsule donor strains (C, D). Serotype-
specific mortality to IPD adjusted for age, comorbidity and other factors as 
described by Harboe et al. (138) is shown on the y-axis. Geometric mean intensities 
of fluorescence (GMF) corresponding to C3 deposition and geometric mean anti-
capsular antibody concentrations required for 50% opsonophagocytic killing are 
shown on the x-axis. Serotypes 3 and 19F (circled) differ from the others by being 
intermediate in resistance to complement yet requiring a high antibody concentration 
for opsonophagocytosis (see Fig. 10). These serotypes were excluded from the 
statistical analysis. Correlation was weaker in panels A (0.48**) and B (-0.25, non-
significant) if serotype 19F was included. In panels C and D the correlations were no 
longer seen if serotypes 3 and 19F were included. *p<0.05, **p<0.01, ***p<0.001, 
Pearson’s correlation coefficient. Data in panels A and B originate from Fig. 4A and 
4B in III. Previously unpublished data is presented in panels C and D. 
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Weinberger et al. described an association between serotype prevalence in carriage 
and the amount of capsular polysaccharide produced in vitro (378). The serotypes 
with less complex polysaccharides were suggested to be associated with a higher 
prevalence in carriage (378). The serotypes more prevalent in carriage were found to 
have a higher risk ratio in bacteremic pneumonia and be more heavily encapsulated 
in vitro (377). A significant association was found between the number of carbons in 
the polysaccharide repeat unit and the severity of IPD caused by different 
pneumococcal serotypes. The serotypes which have the highest IPD mortality and 
which are also the most prevalent in carriage, tend to have the most energy-efficient 
structure (least carbons per polysaccharide repeat unit). The strong negative 
correlation between the severity of IPD and metabolic cost of capsular 
polysaccharide unit synthesis suggests that the serotypes which have a metabolically 
costly capsule, cause less severe disease. However, these serotypes are also the ones 
that are highly invasive. 
 
Disease represents a dead end for the organism, especially when the result is the 
rapid demise of the host (253). In contrast, transmission occurs from the reservoir of 
pneumococci residing asymptomatically in the nasopharynx (16). Why has 
pneumococcus evolved virulent, invasive behavior of certain capsular 
polysaccharide coats? Modeling of interspecies interaction between S. pneumoniae 
and Haemophilus influenzae during experimental colonization indicated that the 
more virulent pneumococcal serotype is able to outcompete the other species and 
survive, even if production of a capsule is otherwise costly (224). Pneumococci 
expressing the avirulent capsule were sensitive to the effects of complement and 
neutrophils, whereas strains expressing the virulent capsule type were not killed 
(224). The capsule type may have a profound effect on not only survival in invasive 
disease, but also on the outcome of mucosal competition by allowing for persistence 
during mucosal inflammation induced by competitive interactions among the 
nasopharyngeal flora.  
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6 CONCLUSIONS 
Opsonization of S. pneumoniae with complement (C3b and iC3b) is a major 
mechanism of immune protection against invasive pneumococcal disease. Like 
many pathogenic bacteria, pneumococcus has several tools to counteract innate 
immunity. Immunization with conjugate vaccines produces opsonic antibodies, 
which enhance complement deposition and clearance of the bacteria. Data from 
clinical studies suggest that the ability of these vaccines to protect against 
pneumococcal disease depends on the serotype. The genotype of the pneumococcal 
strain can also have a significant influence on its virulence both in vivo and in vitro. 
In the work presented in this thesis, I have assessed the relative roles of different 
pneumococcal virulence factors in complement resistance of the species.  
 
The capsular polysaccharide is a major pneumococcal virulence factor that triggers a 
specific immunological response to infection and vaccination. It constitutes an 
important determinant of the potential of pneumococcus to cause invasive and 
severe disease. I found that pneumococcal isolates have different susceptibilities to 
complement deposition and antibody-mediated phagocytosis. The genotype of the 
strain affects its resistance to complement, which was seen as variation between 
strains sharing the same capsule type. However, the results of the studies of this 
thesis studies suggest that the polysaccharide capsule is more important than the 
genotype in determining the resistance of the strain to complement and 
opsonophagocytosis. A higher concentration of anti-capsular antibodies was 
required for the opsonophagocytic killing of the serotypes which were most resistant 
to complement. Serotype-related resistance to complement offers an explanation for 
the differences observed in the efficacy of conjugate vaccines against pneumococcal 
serotypes. Differences in the chemical composition of the capsular polysaccharides 
could partly explain the differences in complement deposition observed between 
serotypes. A low number of available targets for C3b deposition (hydroxyl groups) 
and the presence of acetyl groups in the amino and carboxyl groups of the sugars of 
the capsule polysaccharide appear to be advantageous to resisting recognition by the 
complement system and phagocytic cells. 
 
Differences between serotypes in their ability to activate innate immune responses 
may contribute to disease severity as well as bacterial clearance. The serotypes that 
are able to persist in the respiratory mucosa of healthy individuals are crucial for the 
survival and spread of the bacterium. The prevalence of a serotype in 
nasopharyngeal carriage seems to be determined by the metabolic cost the bacteria 
invest in a capsule. The serotypes associated with a higher prevalence in carriage 
tend to have an energy-efficient structure (less carbons per polysaccharide repeat 
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unit), whereas the capsular polysaccharides of invasive serotypes are more complex. 
The invasive serotypes in general appear to be more resistant to complement and 
opsonophagocytic killing than the opportunistic serotypes. However, invasive 
pneumococcal disease caused by invasive serotypes is associated with a less severe 
outcome. It is possible that the capsule affects not only survival of the bacterium in 
the circulation, but also success in colonization. The latter allows bacterial 
persistence during mucosal inflammation induced by competitive interactions 
among the local microflora. 
 
Although the capsule is significant in many aspects of pneumococcal pathogenesis, 
the virulence proteins are also essential, as demonstrated by the loss of virulence in 
mutant strains. Protection of pneumococci against complement deposition involves 
the coordinated efforts of many different surface proteins. I found that Pht proteins 
may have a role in complement evasion, but their significance depends on the 
genotype of the strain. Other virulence proteins involved in inhibition of 
complement deposition, such as PspA, PspC, and pneumolysin, may compensate for 
the lack of Phts. The main virulence mechanism of Phts could also be other than 
complement inhibition. Immunization with a mixture of these proteins has been 
shown to enhance the survival of mice from pneumococcal carriage or disease in 
previous studies. A combination of pneumococcal protein antigens common to all 
serotypes in a pneumococcal vaccine could provide non-serotype-dependent 
protection. 
 
Both the capsular serotype and the genotype contribute to the virulence of 
pneumococcal strains. In virulent strains, successful combinations of the capsule and 
virulence proteins may have co-evolved into optimal sets of genes. In these 
combinations, the capsule may play the major role – but the same set of proteins 
may act differently with various capsular types. Since certain capsule types endow 
pneumococci with more resistance to complement deposition than others, it is 
apparent that more anti-capsular antibodies are required for efficient 
opsonophagocytosis of the more resistant serotypes. The different susceptibilities of 
different serotypes to complement deposition, opsonophagocytosis, and resultant 
antibody-mediated protection should be taken into account when guidelines for 
serological correlates for vaccine efficacy evaluations are made. 
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